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Physical inactivity has been known to cause deleterious health effects. New 
evidence suggests current physical activity recommendations may not be enough to reduce 
the risk of developing cardiovascular disease and mortality for those experiencing high 
levels of physical inactivity (e.g.; prolonged sitting). The purpose of study one was to 
determine if daily physical inactivity in a group taking low steps (i.e.; 4,767377 steps/day, 
LS) impairs postprandial lipemia (PPL), fat oxidation, and submaximal exercise responses 
to short term training, compared to a group taking high steps (16,048725 steps/day; HS). 
After an initial high fat tolerance test (HFTT) to establish baseline responses to a high fat 
meal, participants (n=16) completed an 11-day training program with assigned step counts 
and five exercise training bouts consisting of 20 minutes of cycling at 80% VO2peak and 
two 5-minute intervals at 90% VO2peak. The day following the first and final bouts of 
exercise training, participants completed a second and third HFTT, respectively, to assess 
acute responses of PPL to the training. Within HS, a 31% reduction (p<0.05) was observed 
 vii 
in plasma triglyceride incremental area under the curve (AUCI) after acute, as well as a 
27% reduction (p<0.05) following chronic training. Further in HS, but not LS, there were 
significant (p<0.05) reductions in markers of stress during submaximal exercise, such as 
blood lactate and heart rate, after training. These findings suggest step reductions can lead 
to an impaired ability to adapt to short term exercise training. The purpose of study two 
was to determine the effect of reducing step count over two days on the ability of a 1-h 
bout of exercise to reduce PPL. Participants (n= 10) completed three trials: Low 
(2,675314 steps/day), Limited (4,759276 steps/day) and Normal Activity (8,481581 
steps/day) for two days followed by a 1-h bout of treadmill running at 64% VO2max with 
a HFTT the following morning. PPL responses following 2,675 and 4,759 step/day trials 
did not differ. However, following exercise in a condition of 8,481 steps/day, AUCI was 
reduced 22% and 23% (p<0.05) compared to the 2,675 and 4,759 step/day trials, 
respectively. This suggests that a 1-h bout of running has a decreased ability to lower PPL 
the next day when taking 4,759 steps/day or less. Taken together these studies highlight 
the importance of maintaining a healthy level of daily non-exercise physical activity, 
regardless of participation in exercise. From these studies it is recommended that 
individuals maintain a daily step count of at least 8,500 steps in additional to any planned 
exercise in order to achieve improvements in PPL as a result of acute or chronic exercise. 
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Chapter I:  General Introduction 
The consequences of physical inactivity have been recognized for four millennia or 
more (19, 20, 112) and the evidence for health benefits of physical activity have been 
clearly documented (68, 203, 208). Nevertheless, physical inactivity continues to be a 
growing problem for the health and wellness of large swaths of the population worldwide 
(105). Physical activity has been almost systematically engineered out of the daily lives of 
many, with advancements in automation and mechanical transport, drastically increasing 
the amounts sedentary time and inactivity overall (9, 26).  The prevalence and effects of 
physical inactivity on health result in an impact on the population that, while not given the 
same attention, is at least as deleterious as that of smoking and obesity (112). However 
drastic the consequence, there seems to be no abatement of this trend in sight (65).  
From the work of Morris (133) through present day investigations physical 
inactivity has been directly linked to at least 35 chronic diseases directly linked to physical 
inactivity (20). Of note in the diseases linked to physical inactivity is atherosclerotic 
cardiovascular disease, which remains the leading cause of both death and disability 
worldwide (6, 78). In 1979, Zilversmit et al. (223) characterized atherosclerosis as a 
postprandial phenomenon. The postprandial or non-fasting state predominates the waking 
hours of individuals in most developed countries, whose population rarely go more than 6-
8 hours without eating a meal. A rise in physical inactivity in these countries leads to 
scenario in which these two regularly coincide and may further amplify the elevation of 
plasma triglycerides which typically peaks 3-5 hours after a meal. If these plasma 
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triglycerides remain abnormally elevated the result is the deposition of fatty plaques in the 
arterial walls which characterizes atherosclerosis (223). 
Current recommendations advise combatting the development of cardiovascular 
diseases, like atherosclerosis, with 30 minutes of moderate-to-vigorous physical activity a 
day or 150 minutes per week (149, 157, 208). Indeed, available evidence clearly documents 
the ability of a single bout of exercise to attenuate the exaggerated rise is plasma 
triglycerides following a meal, or postprandial lipemia (PPL), in individuals who are 
physically active and who normolipidimic (52, 77, 83, 120) and hyperlipidemic (124, 221) 
and across a range of training status (54, 66, 77). Although these well-established (49) and 
newly formed recommendations (39) for exercise are firmly grounded in data driven 
conclusions, it seems some individuals who achieve levels of activity commensurate with 
these recommendations are not incurring the protective effects of said activity (1, 16, 98, 
150, 198, 218). In several recent studies, inactivity has been shown to prevent individuals 
from realizing classic improvements in postprandial triglyceride (1, 98) and glucose (38) 
metabolism following a bout of exercise. Similar impairments have also been shown to 
occur in protein synthesis following prolonged inactivity (22).  
This alarming phenomenon, which has been termed ‘exercise resistance’(98), has 
just begun to be examined and warrants much more investigation. These studies indicate 
that efficacy of exercise, per se, may be diminished or even abolished if it does not coincide 
with a healthy lifestyle characterized by daily physical activity. Therefore, it is important 
to carefully control levels of daily physical activity when examining the protective effect 
of exercise on PPL. While previous investigations have evaluated the response to a single 
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bout of exercise, there are no studies that have investigated the effect of more regular 
exercise bouts over a few weeks, in conjunction with a physically inactive lifestyle. 
Further, the current literature does not clearly delineate at what levels of physical inactivity 
this phenomenon becomes significant. In these studies, we examined 1) the effect of an 
accumulated training stimulus (i.e. 5 training bouts) on PPL and other classic responses to 




Chapter II:  Purpose and Hypothesis 
STUDY #1: Study 1 focused on the adaptations to 5 bouts of exercise training at high 
intensities in two separate groups with a low and a high level of physical activity.  The 
purpose of study 1 was to determine if the background level of daily physical inactivity 
(e.g.; ~4,767 steps/day) impairs postprandial lipemia (PPL) compared to an active control 
condition (e.g.; 16,048 steps/day) and to determine if the background level of daily 
physical activity impairs other cardiovascular and metabolic adaptations to short term 
training compared to an active control condition.  We hypothesized that a low daily step 
count treatment would lead to a lower responsiveness to the exercise training compared 
with a high step count group.  The measurements made include the area under the curve 
for plasma triglyceride (PPL) and fat oxidation in response to a high fat meal, as well as 
post-intervention measures of peak oxygen consumption (VO2peak) and submaximal 
heart rate, blood lactate concentration and muscle deoxygenation.  
 
STUDY #2: Study 2 focused on the effect of inactivity, measured by daily step count for 
2 days on the ability of acute 1-h bout of moderate intensity exercise to reduce the 
postprandial plasma triglyceride and plasma glucose responses to a meal high in fat and 
glucose. The purpose of study 2 was to determine the effect of altering daily step counts 
for two days (i.e.; 2,675, 4,759, and 8,481 steps/day) on the ability of a 1-h bout of 
moderate-intensity exercise to reduce PPL. We hypothesized that increasing daily step 
counts would lead to greater reductions in area under the curve for plasma triglyceride in 
 5 
response to a high fat meal as well increases in fat oxidation, in response to acute 
exercise. This pattern might allow recommendations about the number of steps per day 
needed to achieve a healthy PPL and fat oxidation responses following a high fat meal. 
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Chapter III:  Study #1 
THE EFFECT OF PROLONGED SITTING ON CARDIO-METABOLIC RESPONSES TO SHORT 
TERM EXERCISE TRAINING 
Abstract 
Background: The effects of exercise and physical inactivity on development of 
cardiovascular disease have been evaluated individually in numerous investigations. Yet 
in reality the two interact but the concurrent effects have yet to be fully described. 
Therefore, the objective of the current study was to investigate in young adults, whether an 
inactive group (<5,000 steps/day) responds similarly to short-term aerobic exercise training 
compared to a highly active group (>15,000 steps/day) 
Methods: Sixteen initially sedentary participants completed an intense short-term training 
protocol while taking 4,767377 steps/day (n=8) or 16,048725 steps/day (n=8). 
Participants completed five bouts of training at ~79% VO2peak. Following acute exercise 
and short-term training, metabolic responses to a high fat meal (i.e. plasma triglyceride and 
glucose excursions and areas under the curve and fat oxidation) were assessed during a 6-
hour high fat tolerance test (HFTT) on the morning after exercise and compared to a non-
exercise baseline HFTT completed before the initiation of the training.  Additionally, 
submaximal exercise responses were recorded during 15-minute cycling test (~79% 
VO2peak), including: heart rate, blood lactate, and deoxygenated hemoglobin were 
compared within and between groups, before and after training. 
Results: Maintaining 16,048 steps/day while completing short-term exercise training 
resulted in reduced incremental area under the curve (AUCI) for plasma triglyceride 
concentrations by 31% after acute exercise and by 27% after chronic training, compared to 
baseline (p<0.05). This was accompanied by increased whole-body fat oxidation (p<0.05). 
Further, muscle stress during submaximal exercise, as marked by heart rate, blood lactate 
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and deoxygenated hemoglobin, was also reduced (p<0.05). Despite completing the same 
training regimen, participants taking <5,000 steps/day showed no significant 
improvements in postprandial responses or markers of stress during submaximal exercise 
after training (p>0.05). However, the two groups showed a similar increase in VO2peak. 
Conclusion: In conclusion, when completing a 5-bout exercise training program at 
vigorous intensity, decreasing daily steps to approximately 5,000 steps/day appears to 
prevent or significantly blunt some of the classic cardio-metabolic adaptations that occur 
with 16,000 steps/day. Based on these findings, it appears that the effects of inactivity cause 
a blunting of the normal adaptations to exercise including both cardio-metabolic measures 
as well as exercise stress measures such as heart rate, blood lactate concentrations, and 





The modernization of society has led to vast technological advancements that have 
changed life throughout the world. These advances have intended to improve the quality 
of life for many individuals, and to a degree, increased automation has done so. However, 
the resultant increased physical sedentary time in modernized cultures has been 
accompanied with serious problems. Public health professionals assert that individuals in 
modern society have become a victim of their own success, in which physical activity have 
been systematically “engineered out” of daily life, and further argue that this has 
compromised the health of many (100).  
Couple this with improvements in agriculture and sustainability and people are 
spending more time being inactive in a fed state. Ingestion of fatty foods causes a 
concomitant rise in chylomicron triglyceride concentration in the blood as lipids from 
digestion begin to enter the blood and are subsequently cleared into other tissues over the 
course of up to 8-12 h (32, 56, 86). The rise in chylomicron triglyceride in the blood after 
a meal high in fat produces postprandial lipemia (PPL). The high concentration of 
triglycerides in the plasma leads to subsequent breakdown into more atherosclerotic 
byproducts, resulting in the possible formation of atherosclerotic plaques in arteries (135). 
Along with the rise in sedentary behavior has come an increase in the mortality rate as 
caused by cardiovascular disease (137). As early as 1979, atherosclerosis was described as 
a “postprandial phenomenon” (223). Exaggerated rises plasma triglyceride concentration 
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after a meal (32, 56, 86) caused by a variety of factors including extended periods of 
inactivity (3, 33, 51, 135) may be driving the pathogenesis of atherosclerosis.  
Exercise has been a well-documented method to attenuate the rise in PPL (76, 83, 
120, 168, 222) and prevent a detriment to cardiovascular function (27, 50, 61, 95, 160, 
200). However, recent epidemiological evidence suggest that exercise training may not 
be adequate to reduce incidences of disease and other morbidities, and even death in 
people who spend a large amount of time sitting (70). Despite well-established (49) and 
newly formed recommendations (39), exercise performed concomitant with these 
recommendations may not be enough to overcome the detrimental effects of sedentary 
time.  
New evidence has emerged suggesting prolonged inactivity and sedentary time 
may impede or eliminate the positive effects classically associated with exercise (38, 98). 
In an investigation by Kim et al (98) a group of individuals who sat for >14 h/day for 4 
days did not show the “classic” attenuation PPL that has been shown previously with 60 
minutes of aerobic exercise on the fifth day (99, 183). These authors termed this 
phenomenon “exercise resistance” because it seems exercise was unable to acutely 
improve cardio-metabolic indicators of health (e.g.; PPL and relative fat oxidation). In 
order to counteract this “exercise resistance” due to prolonged sitting higher levels of 
physical activity throughout the day may be needed. In fact, some studies are now 
pointing to the idea that breaking up sedentary time, independent of total moderate to 
vigorous physical activity, may be able to attenuate PPL (38, 69, 153) and restore or 
maintain endothelial function (127, 132, 176). It is also important to systematically 
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evaluate if this “exercise resistance” extends to other typical training adaptations besides 
improved lipid tolerance. 
Most of these studies have evaluated the effect of inactivity time on responses to 
acute (e.g.; one bout) of exercise. Yet, to test a true “exercise resistance” phenomenon it 
would be vital to assess training adaptations incurred over the periods of training than 
longer than simply an acute exercise bout. Thus, it is imperative to determine if short-term 
training adaptations (i.e.; after 5 bouts of exercise training over 9 days) are blunted in 
participants who are also relatively inactive outside of training (i.e.; <5,000 daily steps).  
The purpose of this study is to determine if cardiovascular and metabolic responses 
to exercise are improved in individuals who participate in intense exercise training, yet 
reduce daily steps below 5,000, over the course of 5 training bouts over 9 days compared 
to a group following the same training protocol but are physically active (i.e.; >15,000 
daily steps). We proposed examining the differences in physiological (as assessed via heart 
rate, blood lactate, and NIRS) and metabolic (as assessed by postprandial triglyceride and 
glucose responses) adaptations to short-term training between Low Step (LS) and High 
Step (HS) treatments. We hypothesized LS would exhibit differences in both physiological 
and metabolic adaptations to short-term training compared to HS.  
Methods 
Sixteen healthy, initially sedentary and untrained male (n= 8) and female (n=8) 
participants were recruited and randomly assigned to two groups. Both groups completed 
a training regimen administered under supervision of the investigators. Outside of said 
exercise regimen, one group was physically active (n=8), taking 16,048 steps/day, and the 
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other group was sedentary (n=8), taking 4,767 steps/day. Both groups were asked to refrain 
from any planned exercise outside of the experimental design. Participants were given 
written and verbal description of all the procedures and measurements used in this study, 
and written informed consent was obtained. The Institutional Review Board of the 




The experimental design consisted 17 days with three distinct phases (see Figure 
1). Days 1-3 (Pre-training) consisted of baseline or pre-training measures. Days 4-14 
(Training) consisted of alternating days of training and rest days. The final three days, 15-
17, (Post-Training) consisted of repeating measurements taken in pre-testing phase.  
Following informed consent and completion of a health history questionnaire, On 
the first day participants visited the Human Performance Laboratory (HPL) for initial or 
baseline high fat tolerance test (HFTT). One the second day determination of peak 
oxygen uptake while cycling (VO2peak). The following day, D3, participants completed a 
15-minute submaximal cycling test at 79% of VO2peak value. While the maximal and 
submaximal tests were being conducted, participants wore the activity monitor for 
familiarization purposes. This activity monitor (activPAL, PAL Technologies, Glasgow, 
Scotland)) is small and noninvasive in nature, measuring roughly 2 in x 1in x 0.1in in size 
and worn anteriorly on the thigh. The monitor was placed in a small rubber sheath and 
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attached via transparent film dressing. The activity monitor is not waterproof and cannot 
be worn while showering. Participants were thus instructed to remove the device prior to 
showering and were provided with the materials to change the dressing immediately after 
showering once the area is dry. Therefore, aside from showering, the activity monitor was 
worn continuously throughout the training phase (D4 - D14). After testing on D3, 
participants were asked to refrain from any planned exercise and to begin adhering to the 
prescribed daily step count.  
After the first bout of exercise training on the evening of day 6, another HFTT 
was performed on day 7 to evaluate responses an acute bout of exercise. Participants 
continued the training regimen, exercising and resting on alternating days such that there 
were five exercise sessions and four rest days in this training phase. All exercise bouts 
were identical and consisted of a 20-minute cycling bout at 79% of the participant’s pre-
training VO2peak followed by 10 minutes of rest. Participants then completed two 5-
minute bouts at ~90% VO2peak with 5-minute rest intervals between each bout. This 
exercise prescription is in line with, or exceeds, the current physical activity guidelines 
published by the American Heart Association (AHA) and American College of Sports 
Medicine (ACSM) for improvements in cardiovascular fitness (49).   
In the post-training phase, participants completed a HFTT following the final bout 
of exercise on the evening on D14. On the D15, participants completed another 
submaximal test at the same duration and absolute work rate as the submaximal test 
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during the pre-testing phase (15-minute submaximal cycling test at 80% of VO2peak). On 
the final day participants completed a post-training VO2peak test. 
 
Dietary Control 
During the course of the study participants were asked to eat to satiety, following 
a diet standard in macronutrient breakdown (126).  Also, participants logged all food 
using the MyFitnessPal mobile application (MyFitnessPal, Inc.). Participants were asked 
to consume the same foods on the day prior to each HFTT. On the evening prior to the 
HFTT participants were given a low-fat meal to consume as fat in the previous meal can 
affect the response to a high-fat test meal (42, 184). 
  
High Fat Tolerance Test (HFTT) 
On the morning of the HFTT, participants arrived at the HPL following a 12-hour 
fast and having consumed 500 ml of water 1 hour prior to arrival. Prior to the HFTT, 
participants have body mass was measured. After resting for 5-minutes, an intravenous 
catheter was inserted into an antecubital vein. A resting blood sample was taken and 10-
minutes later, the HFTT test meal consisting of melted ice cream and heavy cream; 
approximately 14.8 kcal/kg (0.8 g, 1.2 g, and 0.2 g/kg BW of carbohydrate, fat, and 
protein, respectively) was consumed in 5-minutes. Blood samples were then taken hourly 
for the next 6-hours.  
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Postprandial Substrate Oxidation 
During the HFTT, expired gas was collected for determination of whole body 
carbohydrate and lipid metabolism. Participants rested for 10-minutes in a seated 
position, followed by 10-minutes of expired gas collection via meteorological balloons 
performed at 0, 2, 4, and 6 hours. It has been previously demonstrated that inactivity 
reduces whole body fat oxidation (98).  
Energy expenditure and substrate oxidation were calculated from oxygen 
consumption, carbon dioxide production, and respiratory exchange ratio (RER), energy 
expenditure and substrate oxidation were calculated based on the methods of Lusk (118), 
below. 
% Energy from carbohydrate (CHO) oxidation = ((RER – 0.707)/0.293) x 100 
% Energy from fat oxidation = 100 – % Energy from CHO oxidation 
CHO oxidation (kcal/min) = (%CHO oxidation/100) x VO2) x 5.05kcal/L O2 
Fat oxidation (kcal/min) = ((1-%CHO oxidation/100) x VO2) x 4.7kcal/L O2 
Energy expenditure (kcal/min) = CHO oxidation + Fat oxidation 
 
Maximal Oxygen Consumption Testing 
 During this procedure, participants breathed into a mouth-piece (while wearing a 
nose-clip) that collected and analyzed the O2 and CO2 content of expired air. From this 
participants oxygen consumption was determined and their peak value (VO2peak) 
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identified. The intensity of exercise, measured in watts, was increased every 1-2 min. 
until they reached their maximal effort level and become fatigued. Volitional fatigue was 
associated with a difficulty or inability to maintain cadence (>60 RPMs) while cycling. 
The total length of the test was ~6-12 min, including a 4-minute warm-up. Heart rate was 
also measured continuously from a strap worn around the chest (Suunto, Vantaa, 
Finland). Heart rate data was used as a validation method for obtaining VO2peak. 
 
Submaximal Exercise Testing 
Submaximal exercise testing was conducted on a cycle ergometer and consisted 
of a 15-minute bout at an intensity of ~80% of VO2peak derived from the VO2peak testing 
described above. Blood samples were taken from an indwelling venous catheter at the 
beginning and end of the 15 min submaximal exercise protocol to evaluate blood lactate 
responses. Heart rate and VO2 were measured continuously, as described above. Near-
Infrared Spectroscopy (NIRS) (OxiplexTS, ISS Oximeter Model 95205, Champaign, IL) 
was used to measure deoxygenated hemoglobin during exercise in the vastus lateralis, as 
a final measure of physiological stress during submaximal testing. The acquisition 
frequency of 2 Hz was used for this study. The data between 9 and 10 minute of the 




For plasma triglyceride and glucose concentrations, all blood samples collected 
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were immediately transferred to K2 EDTA collection tubes (BD Vacutainer, Franklin 
Lakes, NJ), centrifuged at 3,000 g for 15 minutes at 4°C. Plasma was then stored in 
separate aliquots at -80°C until later analysis. All measurements for each participant were 
performed in duplicate within the same analysis. Plasma triglyceride and glucose 
concentrations were measured by a spectrophotometric method using commercially 
available kits (Pointe Scientific, Inc. Canton, USA).  
For blood lactate concentrations, Blood samples were immediately deproteinized 
by placing it in 8% perchloric acid and lactic acid levels were later measured on the 
supernatant. Enzymatic analysis was used to determine blood lactate concentration based 
on methods of Farrell et al (41). Intraassay coefficients of variation for plasma 
triglyceride, glucose, and blood lactate concentrations were all less than 10%. 
 
Statistical Analysis 
 Descriptive Statistics are reported as Mean  SE. Descriptive statistics were 
compared using students t-test (= 0.05). Differences in daily steps, maximal and 
submaximal exercise responses, postprandial responses and incremental (AUCI) and total 
(AUCT) areas under the curve for concentrations of plasma triglyceride and glucose were 
determined by two-way ANOVA (Treatment X Time). Within group differences in 
plasma triglyceride concentration and postprandial substrate oxidation were determined 
using repeated measures two-way ANOVA (Trial X Time). Tukey’s LSD was performed 
to determine if statistical significance exists. All data were analyzed using GraphPad 
 17 
Prism 7 (GraphPad Software Inc., La Jolla, CA). The probability level for statistical 




Participants’ characteristics are described in Table 1. The total number of 
participants was 16 (8 males, 8 females), with each participant randomly assigned to one 
of the experimental conditions. Participants were generally young (23.6  4.7 years), 
healthy individuals that were initially sedentary with similar VO2peak values (HS: 34.1  
3.3; LS: 32.2  2.9 ml/kg/min, p>0.05). There were no differences in age (HS: 23.4.  5.6 
yrs; LS: 23.8  4.0 yrs), height (HS: 166.4  7.9 cm; LS: 167.2  8.4 cm) or body mass 
(HS: 74.4  0.1 kg; LS: 72.5  0.2 kg) between groups (p>0.05). Participant HR, 
%VO2peak, RPE during exercise were all similar (p>0.05) and suggest exercise bouts that 
could be classified as vigorous intensity (Table 2). 
 
Daily Steps 
Daily Steps (Figure 2) were recorded throughout the experimental design. A 
significant main effect was found for treatment group. HS treatment group took 
significantly more daily steps than LS group (HS: 16,048  725 steps/day; LS: 4767  376, 
p<0.001). The groups adhered well to their prescribed step number. However, post hoc 
analyses revealed that on D7, individuals in HS took significantly less steps than the same 
group did on D12 and D14 (D7: 11,096  1361 steps/day; D12: 18,524  2481). These 




Total Plasma Area Under the Curve Responses 
 
Plasma triglyceride concentrations were analyzed at each time point in all trials 
for both treatments and calculated for incremental area under the curve (AUCI) and total 
area under the curve (AUCT) (Figure 3). Plasma TG AUCT & AUCI showed significant 
interactions (Treatment x Time, p< 0.05). Within the LS treatment group, no significant 
differences were found between HFTT time points at Baseline, Acute or Post-training for 
the AUCT or AUCI.   Concurrently in HS, AUCT was significantly lower in both Acute 
(760.9  73.7 mg/dL per 6 h, p< 0.01) and Post Training (762.2  65.5 mg/dL per 6 h, 
p<0.01) as compared with those in Baseline (886.8  79.6 mg/dL per 6 h) with no 
significant difference between Acute and Post Training (p>0.05). The incremental plasma 
TG responses (TG AUCI) was significantly different in both Acute (221.7  49.7 mg/dL 
per 6h, p<0.05) and Post Training (236.7  61.4 mg/dL per 6h, p<0.05) compared to 
Baseline AUCI (322.9  67.2).  Additionally, no differences were detected between 
Acute and Post Training AUCI.  Furthermore, plasma glucose AUCT and AUCI showed 
no significant effects within, or between either treatment groups (p> 0.05) (Figure 4). 
Overall, no between group differences reach statistical at Baseline, Acute or Post-
Training (p>0.05). 
 
Postprandial Substrate Oxidation 
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Postprandial substrate oxidation was determined using indirect calorimetry (Table 
3). Oxidation calculations were limited to 7 participants from each treatment group due to 
possible hyperventilation at rest. Evaluation of postprandial RER data revealed 
significant differences.  Within HS, RERs during the HFTT were reduced after both 
Acute (0.79  0.01) and Post Training (0.80  0.01) compared to Baseline (0.83  0.01, 
p> 0.05). However, but no significant differences were found within LS or between 
treatment groups. Likewise, Percent carbohydrate oxidation and percent fat oxidation 
were found to have significant differences between trials in HS (p<0.05); while no 
differences were seen within LS or between trials. Further, postprandial absolute fat 
oxidation (i.e.; kcal*6h) was higher by 24% in Acute (p< 0.05) and 19% in Post Training 
(p< 0.05) compared with that in Baseline. IN LS, there were no increases in absolute fat 
oxidation during HFTT between Baseline or Acute or Post Training (p>0.05). Finally, 
energy expenditures for the HFTT were not different within or between trials (p>0.05) 
(Table 3). 
 
Plasma Triglyceride & Glucose Concentrations  
Plasma triglyceride and glucose concentrations (Figure 5 & 6) were analyzed at 
Baseline, Acute and Post-training for both treatment groups and calculated for incremental 
area under the curve (AUCI) and total area under the curve (AUCT). In LS, no significant 
difference was found between trials at any time point for the six-hour triglyceride excursion 
(Figure.6).  However, in HS significant differences existed at several time points with 
Acute and Post Training values compared to Baseline. Hour 1, 2 and 3 measurements were 
significantly lower in both Acute and Post Training compared with Baseline (p<0.05).  For 
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the last two measurements (e.g. H5, H6) of the Post Training HFTT were significantly 
lower than baseline (p<0.05) with no differences between Acute and Baseline or Post 
Training. No significant differences were found between trials at any time point for the six-





 Peak and submaximal exercise responses are summarized in Table 2. Peak oxygen 
consumption (VO2peak) increased significantly from pre to post training (p<0.05). Oxygen 
consumption and workload during submaximal exercise was similar between groups pre 
and post training (p>0.05) and showed no difference within groups at either time point 
(p>0.05).  
Blood lactate concentration increased significantly with exercise (p<0.05), while 
no differences existed between groups at rest (p>0.05) or during exercise (p>0.05). Pre-
intervention data showed no significant differences in HR, RPE, RER between groups 
(p>0.05). After five bouts of exercise training, post-intervention testing revealed 
significant reductions in HR and blood lactate concentration within HS (p<0.05), and no 
significant changes in LS (p>0.05). 
 Furthermore, NIRS measurements at rest revealed no differences between groups 
before or after the training (p>0.05). After training, deoxygenated Hb (HHb) was 
significantly lower than pre-testing within the HS group (p<0.05).  No significant 




 Daily caloric intake and percent of macronutrients were averaged across the 11-day 
training phase. HS participants consumed 2389.1  153 kcal/day comprised of 50.7  0.3% 
carbohydrate, 29.8  0.2% fat, & 19.5  0.2% protein. Daily caloric intake for LS averaged 
1949.9  47 kcal/day comprised of 51.9  0.4% carbohydrate, 29.2  0.5% fat, & 18.9  
0.2% protein. Caloric intake was significantly different between groups (p<0.001) No 




This study investigated the effect of 11 days of inactivity (<5,000 steps/day) on the 
ability of a short-term exercise training regimen, consisting of 5 bouts over 9 days, to 
improve postprandial triglyceride and classic markers of training adaptation. The foremost 
finding was that, against a background of reduced daily steps (i.e.; low step; LS), intense 
training (i.e.; 20-minute exercise bout at 80% VO2peak with two 5-minute intervals at 95% 
VO2peak) failed to improve the postprandial metabolic responses to a high-fat meal or 
promote classic whole body adaptations during submaximal exercise. This is noteworthy, 
in that exercise of this intensity and duration was found to elicit sizable improvements in 
high step (HS) as observed previously (46, 124, 183). In those who are active (e.g.; HS), 
our findings suggest that a single acute bout of the prescribed exercise was effective in 
lowering postprandial TG. Both AUCT and AUCI were significantly lower than baseline 
after an acute bout of exercise, in the HS group accumulating ~16,000 daily steps. 
Following four additional bouts of the same exercise postprandial metabolic responses 
were similar to those seen after the single acute bout. Thus, the exercise was effective at 
lowering PPL in an active group taking ~16,000 steps/day and additional bouts of training 
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appear to offer no greater benefit compared to a single bout. This agrees with previous 
observations suggesting no additive effect of exercise bouts of consecutive days (40, 45).  
Therefore, it seems that a reduced daily step count may somehow prevent or 
severely encumber the healthy cardiometabolic adaptations that normally occur in response 
to this training, both acute and chronically (46, 76, 77, 81, 83, 120, 221). This inability to 
derive the protective effects of training, caused by physical inactivity, agrees with the 
phenomenon of ‘exercise resistance’ first postulated by Kim et al (98). Further, this study 
is the first to provide evidence that the implications of exercise resistance may extend to 
short-term training.  
While Kim et al (98) and one other study (1) also induced exercise resistance by 
reducing daily steps to <2000 and <4000 steps/day, respectively,  and used similar HFTT 
testing procedures, these prior observations were limited to acute exercise bouts. In both 
these studies a 1-h hour bout of exercise at ~65% VO2max failed to improve postprandial 
metabolic responses, as would typically be seen following exercise of this duration and 
intensity (76, 120, 167, 222). The present design contributes significantly in expanding the 
consequences of daily physical inactivity beyond responses to a single bout of exertion into 
a paradigm of more regular exercise that would fit within current recommendations (157).  
Indeed, epidemiological studies have clearly documented that individuals who meet 
current recommendations may not realize the reduced risk of CVD usually associated with 
meeting guidelines, if these individuals are also inactive for the remainder of the day (16, 
65). As others have noted (64, 65, 181, 205) it is possible, if not likely, that people living 
in the US and similar industrialized countries could achieve or exceed physical activity 
guidelines while still being inactive for 15 or more hours each day.  It seems this interplay, 
of prolonged inactivity and exercise, reduces the potency of the stimulus provided by 
exercise training (1, 38, 98). However, there is a dearth of data on how the consequences 
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of this interplay would manifest themselves with even short term training as presently 
employed. That is to say, while exercise resistance has been shown following acute 
exercise, one might not expect the same results from a single bout of exercise to be derived 
from short-term exercise training (96, 157). The findings from this investigation provide 
evidence explaining, in part, the observations seen in previous epidemiological studies that 
have found some individuals who are meeting published guidelines on physical activity are 
not realizing reduced risk of CVD and premature mortality (16, 39, 150, 198, 218). 
The findings from this study suggest individuals meeting current physical activity 
guidelines may not derive the protective effect of daily physical activity to improve health, 
at least in regard to postprandial triglycerides, if they are also experience extended periods 
of inactivity. Our finding that, in a group of individuals taking 4767 steps/day, postprandial 
responses were similar to untrained baseline whether individuals performed a single bout 
of exercise or five exercise bouts is noteworthy. Further the exercise performed in this 
study was a higher intensity (i.e. ~80-90% VO2peak) than in previous studies noting 
exercise resistance (1, 98). This is significant in that higher intensity exercise has been 
shown to exert greater PPL lowering effects than moderate, or low intensity (99, 183) and 
may provide additional insight into the potency of the induced ‘exercise resistance’.  
While our findings did not suggest an additive effect of the final four training bouts 
for lowering PPL beyond the acute response to exercise, it is important to note that the 
consistent exercise sessions should not be viewed as ineffective. It is probable that the TG 
lowering effect of the training was exerted after each additional bout, not just after the first 
and final bouts when HFTTs were performed, serving to maintain consistently-low daily 
plasma TG levels. Regular exercise is likely to have beneficial effects on PPL through 
short-term increases in LPL (164) as well as the other cardiovascular benefits generally 
(149). 
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Among these cardiovascular benefits are indicators of muscular stress that are 
typically reduced following exercise training while exercising at a given intensity. These 
measures such as heart rate and blood lactate accumulation seem to be similarly unaffected 
in LS compared to HS.  While our findings clearly demonstrate that both conditions (high 
and low step count) benefited from training, by increasing their VO2peak and thereby 
decreasing the relative percentage of VO2peak needed to sustain an absolute work rate 
while cycling, it seems adaptations at the level of the muscle (i.e.; blood lactate) may have 
been impaired. It is unlikely that the changes seen in HS were due to the higher number of 
steps causing an additional training effect beyond that provided by the intense training (80-
90%VO2peak), but that possibility can’t be discounted. Individual who simply increase 
their daily step count over several weeks, typically don’t increase VO2max or show the 
adaptations to submaximal exercise currently seen in HS (170).This study could have 
benefitted from an additional control group in which participants maintained a high step 
count but did not participate in the short-term training. This would have allowed isolation 
of the effects of increasing daily activity alone. While is it probable that this level of daily 
walking, in HS, was somewhat higher than the participants would experience during 
normal daily living, it is highly unlikely that the intensity of walking (e.g. ~30% VO2max) 
elicited significant adaptation (212). This suggests the lack of improvement in blood lactate 
in LS pre-vs-post training may be due to inactivity producing an intramuscular 
environment that might be ‘resistant’ to the stimulus provided by training.  
Reductions in daily steps, whether imposed by prolonged sitting or another form of 
induced inactivity may lead to a condition in which uptake of substrates in the blood by 
muscle is reduced. While this requires speculation, it is possible that the similar levels of 
blood lactate, plasma triglycerides, and plasma glucose where due to decreases in cellular 
expression or activity of membrane transporters such as MCT, GLUT4, and GPIHBP1 
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proteins responsible for increased uptake of these energy substrates. Disuse, modeled 
through denervation of a rats hindlimb resulted in decreases in MCT1 in the soleous and 
MCT4 in the gastrocnemius (210). Because muscle serves as a primary consumer of lactate 
during exercise, any decreased expression of MCTs could lead to increased lactate 
concentrations during steady state exercise, or the lack of improvement blood lactate levels 
seen in LS. Similarly It has been suggested that  hindlimb suspension could result in 
decreases in GLUT4 expression at the surface of the sarcolemma (94). 
Recent observations support this contention in that not only is the postprandial 
triglyceride response impaired with inactivity but a plethora of other metabolic responses 
may be diminished or abolished as well (1, 13, 38). Consistent with our findings, 
Bergouignan et al. (13) showed that 32 days of bed rest increased PPL by 27%, compared 
to an ambulatory control, and this effect was not averted by exercise training performed 
every 3 days during the bed rest. Duvivier et al. (38) showed an hour of exercise was not 
sufficient to counteract the effects of sitting for 13 hours which resulted in no significant 
improvements in triglycerides, non-HDL cholesterol and apolipoprotein B plasma levels 
compared to a sitting condition without exercise. Interesting a group with matched energy 
expenditure through increased daily walking did see improvements in each of those 
measures, compared to sitting plus exercise, without structured exercise(38). Further 
reduced myofibrillar protein synthesis can be seen in elderly (22) and young healthy 
individuals (166) in response to step reductions of two weeks or less. This could be due to 
reduced uptake of amino acids from circulation, similar to the reduced plasma triglyceride 
and plasma glucose uptake shown by this study and others (1, 13, 98).  
Primary amongst the limitations of the current study was a lack of sufficient power. 
Power analyses indicated that a sample size of approximately 38 individuals would be 
necessary to detect between groups differences in triglyceride AUCI. Despite sizable 
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differences in postprandial triglyceride responses within the respective treatments, it is 
likely that this lack of power prevented our ability to detect difference between our 
treatment groups, both in postprandial and exercise responses. Therefore, while it can be 
concluded that the short term exercise training significantly improved PPL both acutely 
and chronically in HS, whereas it did not significantly improve PPL in LS, it cannot be 
concluded that HS was found to be significantly better than LS. 
Secondly, it is possible that our results were influenced by selection bias. 
Participants were all previously sedentary, and were randomly assigned to each ‘step’ 
group. It is unclear if that those who participated in the study are fully representative of a 
broader sedentary population, as they sought out an opportunity to participate in intense 
exercise testing and training and were willing to commit to and strictly follow a structured 
program of that nature. 
Participants in the study, especially within LS, also began to wane from strict 
adherence to the daily step protocol as the training phase progressed. Due to the nature of 
the study, extending 11 days across 2-3 weekends, to carefully ensure adherence to the 
assigned daily step goal would have caused an undue burden on the participants in this 
study by removing them from their normal routine. Having participants remain in the 
laboratory or under direct observation is impractical for the scope of this work. Despite 
taking more than 6,000 steps/day on a few days prior to the ‘Post Training’ HFTT (D10, 
D12, and D13), the relative increase in daily steps seems to have little effect on the 
postprandial responses. This is evidenced by similar AUCI during ‘Acute’ and ‘Post 
Training’ HFTTs while taking less than 4,400 step/day, on average, in the days preceding 
the ‘Acute’ HFTT. This may indicate that 6,000 steps/day is also inadequate to counteract 
‘exercise resistance’ and realize the protective effects of exercise training, at least in terms 
of PPL. Currently, however, this requires speculation as ‘exercise resistance’ has only 
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recently been recognized (98)) and the nature of its development and abatement have yet 
to be fully described. That is, we cannot say conclusively that 6,000 step/day results in the 
development exercise resistance in the absence of prior days of an even further reduced 
daily step count as presented here. Further work is needed to address these issues 
definitively. 
In conclusion, the data presented here suggest that 11 days of step reduction (i.e.; 
LS; 4,767 steps/day) prevents the improvements in PPL typically seen following intense 
exercise training when background step count is high (e.g.; HS: 16,048 steps/day). Instead 
of reductions in TG AUCs, as seen with training in HS, the results indicate no 
improvements compared to baseline after acute exercise or short-term training. The finding 
from the current investigation indicate that reducing steps below approximately 5,000 
steps/day may generate reduced responsiveness to normal, healthy stimuli of intense short-
term exercise training. These findings suggest that reliance on exercise may not be enough 




Tables and Figures 
 
 
Figure 1. Study Design. Participants were separated into two groups (High Step or Low 
Step) and completed a short-term exercise regime with physiological and metabolic 




Figure 2. Daily steps were measured via activPal activity monitor, attached on the 
participant’s anterior thigh throughout each trial. Average daily step count, for each 
group are presented for the 11-day intervention period (D4-D14). Average daily steps 
were significantly different between groups for every day measured (p<0.001). (*) 
significantly different from D12 and D14 within treatment group (p<0.05). 
  
























Figure 3. Total and Incremental areas under the curve of plasma triglyceride 
concentration during HFTT at Baseline, following a single bout of exercise (Acute), and 
following 5 training bouts over the 9-days of training (Post Training). (*) Significantly 
different from Baseline within treatment group, p<0.05. (†) significantly different from 
Baseline within treatment group, p<0.01. Data reported as meanSE.  























































Figure 4. Total and Incremental areas under the curve of plasma glucose concentration 
during HFTT at Baseline, following a single bout of exercise (Acute), and following 5 
training bouts over the 9-days of training (Post Training). Data reported as meanSE. 
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Figure 5. Temporal responses of plasma triglyceride & plasma glucose concentrations 
for High Step treatment during the HFTT at Baseline, following a single bout of exercise 
(Acute), and following 5 training bouts over the 9-days of training (Post Training). (*) 
Acute significantly different from Baseline, p< 0.05. (†) Acute & Post Training 
significantly different from Baseline, p< 0.01. (#) Post Training significantly different 
from Baseline, p<0.05. Data reported as meanSE. 

















































High Step Plasma Glucose Response
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Figure 6. Temporal Responses of plasma triglyceride & glucose concentrations for Low 
Step treatment during HFTT at Baseline, following a single bout of exercise (Acute), and 
following 5 training bouts over the 9-days of intervention (Post Training). Data reported 
as meanSE. 
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Physical Characteristics High Step (n=8) Low Step (n=8) 
M/F 4/4 4/4 
Age (y) 23.4  2.0 23.8  1.4 
Height (cm) 166.4  2.8 167.2  3.0 
Body Mass (kg) 74.4  5.9 72.6  3.9 
BMI (kg/m2) 26.7  1.9 25.9  1.0 
Note: Data are reported as MeanSE 
Table 1. Descriptive statistics of the two groups (i.e. High Step and Low Step) at the 





High Step Low Step 
Pre Post Pre Post 
Absolute VO2peak 
(L/min) 2.51  0.3 2.70  0.2† 2.35  0.2 2.52  0.3* 
Relative VO2peak 
(mL/kg/min) 
34.1 ± 3.3 36.9  3.6† 32.2 ± 2.9 34.5  3.3* 
Submaximal VO2 
(L/min) 
1.98 ± 0.7 1.98  0.9 1.87 ± 0.6 1.88  0.2 
%VO2peak 78.3  0.8 72.5 1.8† 79.9  0.7 75.3  1.3* 
Heart Rate  
(bpm) 
181.4 ± 4.7 168.8  4.6† 180.9  5.3 175.8  4.1 
HHb  
(AU) 




7.6  0.8 6.7  0.8* 7.2  0.3 7.2  0.4 
RPE 15.6 ± 0.8 13.8  0.5 15.8  0.4 14.5  0.6 
Workload 
(W) 
135.1  18.7 -- 125.6  15.3 -- 
 Note: Data are reported as MeanSE. (*) Significantly different from Pre, p<0.05. (†) 
Significantly different from Pre, p<0.01 
Table 2. Physiological responses to maximal and submaximal exercise testing. (*) 
significantly different from pre-testing within treatment group, p<0.05. (†) significantly 







Baseline Acute Post Training Baseline Acute Post Training 
RER 0.83  0.01 0.79  0.01* 0.80  0.01* 0.83 0.01 0.82  0.01 0.81  0.01 
Fat Oxidation (%) 58.5  3.18 70.7  2.32* 67.3  2.10* 57.7  3.89 62.6  2.81 63.9  2.57 
Fat Oxidation (kcal/6h) 310.2  18.2 384.1  25.1* 368.9  16.5* 330.4  37.2 351.8  43.4 350.7  29.2 
CHO Oxidation (%) 41.5  3.18 29.3  2.32* 32.7  2.10* 42.3  3.89 37.4  2.81 36.1  2.57 
CHO Oxidation 
(kcal/6h) 
216.6  19.1 157.8  11.9 181.2  13.7 233.9  22.5 203.5  11.3 201.1  23.1 
Total Energy 
Expenditure (kcal/6h) 
526.8  18.7 541.9  26.3 550.1  18.6 564.3  39.6 555.3  45.2 551.8  43.9 
Note: Data are reported as Mean  SE. 
Table 3. Overall postprandial substrate oxidation during HFTTs at Baseline, following a 
single bout of exercise (Acute), and following 5 training bouts over the 9-days of training 




Chapter IV:  Study #2 
DOSE RESPONSE OF PHYSICAL INACTIVITY ON PLASMA TRIGLYCERIDES AFTER A 
MEAL 
Abstract 
Background: It has been suggested that there is a linear, inverse dose-response 
relationship between the daily steps and cardiovascular events. However, it seems if 
individuals severely reduced the number of steps taken throughout the day the protective 
effects of exercise may not be realized. The objective of this study was to determine 
differences in postprandial metabolic responses following acute exercise against a 
background of differing levels of daily step reduction. 
Methods: Ten participants completed three, five-day trials in a randomized, crossover 
design with differing levels of daily step reduction. Following two days of controlled 
activity, participants completed two days of Low, Limited, or Normal Activity (2,675, 
4,759, or 8,480 steps/day, respectively). Participants also completed a one-hour bout of 
exercise on the evening of the second day of step reduction. A high fat tolerance test was 
performed on the following morning. Postprandial responses were compared in each trial. 
Results: Daily steps were significantly different in each trial (2,675, 4,759, or 8,480 
steps/day, respectively; p<0.05) while responses to the acute moderate intensity exercise 
were similar (p>0.05). Following the NORM trial, participants’ incremental plasma 
triglyceride response was lower than LIM by 23% (p<0.05) and LOW by 22% (p<0.05). 
Whole body fat oxidation was also significantly increased in NORM compared to the two 
other trials (p<0.05). No significant differences were found between LIM and LOW in any 
postprandial measure. 
Conclusion: In conclusion, two days of daily step reduction in young healthy individuals 
can impair the ability of acute exercise to attenuate PPL. The finding that the participants 
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don’t lower PPL or increase fat oxidation in response to exercise when taking ~4700 steps 
or less, may indicate a reduced responsiveness of skeletal muscle to exercise. This agrees 
with the newfound phenomenon of ‘exercise resistance’ in individuals whose daily life is 




The cardio-metabolic health benefits of physical activity and exercise such as 
improved postprandial hypertriglyceridemia and improved glucose tolerance, can be 
gained acutely from a single bout of exercise and lost with several days of inactivity (80, 
82, 83).  However, studies in which acute exercise resulted in reduced postprandial 
hypertriglyceridemia, the participants were accumulating approximately 7,000-8,500 
steps on the day before evaluation of postprandial metabolism (99, 183, 184).  Although, 
in a recent study Kim et al. (98), the authors reported that in participants who were sitting 
for >14 h/day and taking only 1,650 steps/day, a one-hour bout of running at 67% 
maximal oxygen consumption (VO2max) failed to improve postprandial 
hypertriglyceridemia the next morning.  It seems that physical inactivity (i.e; severely 
reduced step count) rendered the participants resistant to the normal acute improvements 
in indices of cardio-metabolic health that are normally derived from a one-hour bout of 
running. This phenomenon is referred to as ‘exercise resistance’ (98). A follow-up study 
in 2019 (1), used additional controls to verify the existence of this phenomenon found a 
group taking ~3700 steps/day also exhibited exercise resistance. Therefore, it is important 
to systematically delineate what magnitude of daily step reduction causes impairment of 
the ability of acute exercise to improve the postprandial plasma triglyceride response.   
In modern culture, we have engineered physical activity out of our daily lives. 
Periods of prolonged inactivity, characterized by mostly sitting, have become routine in 
the lives of many and routinely coincide with the non-fasting or postprandial state. In the 
postprandial state, triglyceride levels in the plasma can remain elevated for up to 10 
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hours, typically peaking 3 - 6 hours after a meal rich in fat (152). The magnitude and 
duration of this elevation is influenced by prior physical activity (52, 120, 221), diet 
(174), and genetics (173, 204). As demonstrated in recent epidemiological studies (5, 
142), non-fasting plasma triglyceride levels, i.e., post-prandial lipemia (PPL), better 
predicts cardiovascular events than fasting plasma triglyceride levels and are known to be 
associated with diseases, including metabolic syndrome, type 2 diabetes, and 
atherosclerosis. In fact, several recent epidemiological studies, inactivity and/or sitting 
time has been strongly associated with the risk of obesity, metabolic disorders including 
type 2 diabetes mellitus and especially with cardiovascular disease and death (16, 198, 
218).  Surprisingly, some have reported that the risks from prolonged sitting appears 
“independent” of the volume of exercise being performed (16, 150, 198, 218). This 
means people who meet the recommended guidelines (AHA or ACSM) for physical 
activity of 150 min/week of moderate intensity exercise appear to still be at risk for 
developing cardiovascular disease and all-cause death if they have a lifestyle routinely 
incorporating prolonged periods of inactive, sedentary behavior (>10-12 h/day).   
One of the strongest negative correlations (r=-0.96) in relation to sedentary time is 
time in light-intensity activity, such as walking (65). This means increasing time spent 
ambulatory reduces sitting time. Accordingly, manipulation of daily step count has been a 
popular and potent method of studying the effects of inactivity. Appropriately, increased 
daily walking has been shown to reduce cardiovascular events (122) while reductions in 
daily step number for as little as one week have been associated with drastic increases the 
area under the curve of plasma  insulin during an oral glucose tolerance test (OGTT) 
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(145). This increase showed the potential to grow to nearly 80% greater, if the reductions 
were maintained for 2 more weeks (145). Daily step reductions have also been linked to 
decreased VO2max, endothelial dysfunction, decreased insulin sensitivity, decreased lean 
leg mass and increased abdominal fat (22, 109, 145). 
 Meanwhile, it is well established that a single bout of moderate exercise lasting 
60-90 minutes attenuates PPL regardless of prior lipid levels (221) and training status 
(66, 120, 151). Many studies (52, 120, 221) have been conducted to investigate the effect 
of a single bout of moderate intensity exercise on postprandial triglyceride levels in 
comparison to a control condition. Participants in these studies were asked to refrain from 
any planned exercise but their ambulatory activity, including walking, was not carefully 
controlled. Furthermore, very few studies (1, 98) have investigated the collective effect of 
daily step reduction and moderate exercise. Although recent data (1) present compelling 
evidence that drastically reducing daily step number may abolish the ability of an acute 
bout of exercise to attenuate the increase in PPL, some other studies seem to suggest this 
may not occur with as little as ~7,900 steps/day (183).   
Thus, the purpose of this study was to investigate the effect of reductions in daily 
step number and a single 1h bout of moderate intensity exercise on postprandial 
concentrations of plasma triglyceride and glucose, as well as fat oxidation. We 
hypothesized that postprandial responses, following a single bout of 1-hour of running at 
65% VO2max, would differ as daily steps increased. 
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Methods 
Ten healthy untrained, recreationally active male (n=7) and female (n=3) 
participants completed three different trials of differing daily step counts based on 
previously established cut-points for physical activity (194). Participants were assigned to 
Low Activity (LOW): 2675 steps/day, Limited Activity (LIM): 4,759, and Normal Activity 
(NORM): 8480 steps/day in a randomized, crossover design, each occurring over five days 
with at least a week interval between trials (See Figure 7). Participants were asked to refrain 
from any planned exercise outside of the experimental design. Participants were given 
written and verbal description of all the procedures and measurements used in this study, 
and written informed consent was obtained. The Institutional Review Board of the 




Each trial consisted of three phases: the first two days served as a control phase 
(C1 and C2), that allowed for familiarization and control, followed by a 2-day 
intervention phase consisting Low, Limited, or Normal physical activity consisting of 
daily step counts of 2,675, 4,759, or 8,480 steps per day, respectively, with 1-h of running 
on the evening of the second day of each trial at 64% VO2max on a laboratory treadmill.  
On the morning of Day 3 all participants ingested a high fat shake (i.e.; high fat tolerance 
tests; HFTT) and the postprandial responses were measured over the subsequent 6h 
period.  Throughout the three trials, participants were instructed to refrain from any 
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exercise other than that prescribed in the study design. Participants were also asked to 
keep a consistent sleep/wake cycle during the trials. 
 
Preliminary Testing 
One week prior to the initiation of the first trial, participants visited the Human 
Performance Laboratory (HPL) for a 20-min, 4-stage submaximal test to determine 
oxygen consumption while jogging at different paces followed by determination of 
maximal oxygen uptake (VO2max). This served to determine the appropriate treadmill 
speed to elicit the desired intensity during the 1-h exercise bout. In order to determine 
VO2max participants performed an incremental treadmill test lasting 8-12 minutes during 
which the incline was increased 2% every 2 minutes (29). VO2, VCO2, and heart rate 
were monitored throughout the test, and the highest 30 second VO2 average was recorded 
for the participant’s maximal oxygen consumption. The ACSM criteria for VO2max was 
used in assessing a successful VO2max test. These criteria are: a plateau in oxygen 
consumption (less than 150 ml/min increase in VO2 with increasing work), respiratory 
exchange ratio (RER) >1.1, maximal heart rate within 10 bpm of predicted maximal heart 




Participants were instrumented with an activity monitor worn on their thigh to 
record step count (activPAL, PAL Technologies, Glasgow, Scotland) and the monitor 
began recording at 0:00hrs on the first day of the control phase (C1). Participants were 
asked to remain aware of their step count and to limit steps to 8000 or less to approximate 
a non-sedentary, low level of physical activity (189). If participants were unable to 
achieve 8,000 step limit in their first trial, they were the asked to repeat their activity as 
closely as possible during the control phases of the subsequent trials. 
 
Intervention Phase 
 During the intervention phase, D1 & D2, participants were asked to remain seated 
or lying for much of the day to accommodate their assigned level of non-exercise activity 
(2,675, 4,759, or 8,480 steps/day). On D2 of each trial participants continued to adhere to 
the assigned step count, but completed a 1-h run at 64.4% VO2max at 18:00h. The steps 
during this bout of exercise were not included as part of the participants total for D2. 
 
High Fat Tolerance Test (HFTT) 
Participants were given a low fat meal the evening prior to high fat tolerance test 
(HFTT) given that the plasma TG response to a high fat shake (HFS) may be affected by 
the fat content of a previous meal (42). On the day of the HFTT (D5), participants 
reported to the laboratory at 07:00 h. Body weight was measured. They then lie on a 
padded table for 5 minutes before insertion of a catheter into an antecubital vein. A 
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fasting blood sample was collected 10 min before consumption of a high fat shake (HFS) 
(mostly melted ice cream and heavy cream; approximately 14.8 kcal/kg (0.8 g, 1.2 g, and 
0.2 g/kg BW of carbohydrate, fat, and protein, respectively). Participants were asked to 
consume the HFS in 5 minutes. Blood samples were collected over the next 6 hours at 0, 
2, 3, 4 and 6h post consumption of the HFS. All blood samples collected were transferred 
to K2EDTA collection tubes (BD), centrifuged at 2,000 g for 15 minutes at 4◦C and then 
stored in -80◦C freezer until later analysis. During HFTT, participants were asked to 
remain seated quietly reading, watching movies, and/or surfing the internet. Participants 
were allowed to  
 
Postprandial Substrate Oxidation 
Postprandial expired gas collection was used for indirectly assessing substrate 
oxidation. Participants rested in a chair for 10 minutes, followed by expired gas 
collection through meteorological balloons for 10 minutes at 0, 2, 4, and 6 h.  It has been 
previously demonstrated that inactivity reduces whole body fat oxidation (98).  
Energy expenditure and substrate oxidation were calculated from oxygen 
consumption, carbon dioxide production, and respiratory exchange ratio (RER), energy 
expenditure and substrate oxidation were calculated based on the methods of Lusk (118). 
% Energy from carbohydrate (CHO) oxidation = ((RER – 0.707)/0.293) x 100 
% Energy from fat oxidation = 100 – % Energy from CHO oxidation 
CHO oxidation (kcal/min) = (%CHO oxidation/100) x VO2) x 5.05kcal/L O2 
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Fat oxidation (kcal/min) = ((1-%CHO oxidation/100) x VO2) x 4.7kcal/L O2 
Energy expenditure (kcal/min) = CHO oxidation + Fat oxidation 
 
Dietary Control 
During the course of the study participants were asked to eat to satiety. 
Participants logged all food and were asked to consume the same foods on the day prior 
to each HFTT. On the evening prior to the HFTT participants were given a low-fat meal 
to consume as fat in the previous meal can affect the response to a high-fat test meal (42, 
184). Participants were allowed to supplement higher energy expenditure during the LIM 
and NORM step trials with a small snack but were asked to adhere to a diet standard in 




For plasma triglyceride and glucose concentrations, all blood samples collected 
were immediately transferred to K2 EDTA collection tubes (BD Vacutainer, Franklin 
Lakes, NJ), centrifuged at 3,000 g for 15 minutes at 4°C. Plasma was then stored in 
separate aliquots at -80°C until later analysis. All measurements for each participant were 
performed in duplicate within the same analysis. Plasma triglyceride and glucose 
concentrations were measured by a spectrophotometric method using commercially 
available kits (Pointe Scientific, Inc. Canton, USA). Intraassay coefficients of variation 




Incremental (AUCI) and total area under the curve (AUCT) for plasma triglyceride 
and glucose were calculated. Once calculated, repeated measures one-way analysis of 
variance (ANOVA) was used to test for differences. Plasma glucose and triglyceride curves 
were calculated and analyzed using repeated measures two-way ANOVA (trial x time). 
Daily step counts were analyzed using repeated measures two-way ANOVA (trial x time). 
Similarly, respiratory exchange ratio (RER), as well as fat and carbohydrate oxidation, 
were analyzed using repeated measure two-way ANOVA (trial x time). When interactions 
were significant, Tukey’s honestly significant difference post hoc tests were run. All data 
were analyzed using GraphPad Prism 7 (GraphPad Software Inc., La Jolla, CA). All data 
are expressed as mean  standard error of the mean (SE), unless otherwise noted, the level 
for statistical significance was set at p  0.05.  
Results 
Participant Characteristics 
 Participant characteristics are summarized in Table 4. A total of 10 participants 
were recruited (7 males, 3 females), with all participants completing all three trials. 
Participants were apparently healthy, young adults (24.0 ± 1.8) that were untrained to 
recreationally active. 
 
Responses to Maximal and Submaximal Exercise 
 Responses to maximal and submaximal treadmill running are shown in Table 5. 
Submaximal exercise bouts elicited a heart rate of 153.9  3.9 bpm and an oxygen 
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consumption of 2210.2  154 ml/min, which equated to approximately 64.4% of 
participants VO2max. These responses were indicative of moderate intensity exercise and 
were not different between trials. 
 
Daily Steps  
 Daily steps are presented in Table 6. A significant Trial x Time interaction was 
found daily step count (p<0.001). Post hoc analyses revealed no significant differences 
within or between trials for control days (p>0.05). However, daily steps on Day 1 of the 
intervention were significantly different for all trials (LOW: 2,744331, LIM: 4,482318, 
NORM: 8,431732). Likewise, during Day 2 of the intervention, excluding exercise steps, 
daily steps were significantly different for all trials (LOW: 2,605313, LIM: 5,037206, 
NORM: 8,530420; p<0.01 for all comparisons). 
 
 
Total Plasma Area Under the Curve Responses 
 
Plasma triglyceride concentrations were analyzed at each time point in all trials 
for all trials and calculated for incremental area under the curve (AUCI) and total area 
under the curve (AUCT) (Figure 8). Analysis of plasma TG AUCT revealed significant 
differences with NORM being significantly lower than LOW (p<0.01) and a trend toward 
difference compared to LIM (p=0.09). AUCI in NORM (267.539.2 mg/dL*6h) was 
significantly different from LOW and LIM (342.347.8 and 348.648.9 mg/dL*6h, 
respectively, p<0.05). No differences were detected between LOW and LIM in AUCT, 
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nor AUCI. Plasma glucose areas under the curve showed no differences (p>0.05) 
between the three trials in AUCT or AUCI (Figure 9). 
 
Plasma Triglyceride & Glucose Concentrations  
Plasma triglyceride and glucose concentrations were analyzed at each time point in 
all trials for both treatments. Triglyceride and glucose excursions are shown in Figure 10 
for TG, and Figure 11 for glucose. Significant differences existed at multiple time points 
between trials. At hours 2 and 3, NORM was significantly different from LOW (p<0.05). 
At hour 3, NORM was also significantly different from both LIM (p<0.05). NORM was 
also significantly different from LOW (p<0.01) and LIM (p<0.05) at hour 4. No differences 
existed at baseline or hour 6 for triglyceride concentrations (p>0.05). Furthermore, no 




Postprandial Substrate Oxidation 
 Postprandial substrate oxidation was determined using indirect calorimetry (Table 
8). Postprandial RER was significantly different in NORM (0.770.01) compared to LOW 
(0.800.01, p<0.05) with a strong trend toward significant from LIM (0.81 0.01, p=0.06).  
Similarly, percent fat and carbohydrate oxidation, as well as absolute carbohydrate 
oxidation (i.e. kcal*6h) were different in NORM compared with LOW (p<0.05). Notably, 
Absolute fat oxidation was significant different in NORM (396.027.5 kcal), compared 
with LOW (318.934.5 kcal, p<0.05) and LIM (342.430.9, p<0.05).  
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Post hoc analysis for bihourly RER measurements (Appendix F) revealed 
differences for hour 2 between NORM and both LOW and LIM (p<0.05), while RER was 
similar between trials at other measurement time points (p>0.05). Similarly, differences in 
percent fat oxidation and percent carbohydrate oxidation were significant at hour 2. Finally, 
no difference was found between trials in overall postprandial energy expenditure, or 
energy expenditure at any single time point between or within trials (p>0.05).  
 
Discussion 
The purpose of this study was to investigate the effect of daily step reductions on 
postprandial responses to a high fat meal the morning after an acute bout of moderate-
intensity exercise. We hypothesized our key measures, TG AUCI, and fat oxidation would 
display a curvilinear dose-response relationship with daily steps taken in the two days 
preceding an acute exercise bout. The primary finding of this study was that when 
individuals take ~8500 daily steps their postprandial triglyceride responses and whole body 
fat oxidation during a HFTT, following 1-hour of exercise at 64% VO2max, the night before 
were significantly improved compared with the same individuals taking 4,759 steps/day or 
2,675. In this randomized, cross over experimental design individuals displayed a 23% and 
22% reduction in TG AUCI when averaging 8480 steps/day, compared to those same 
individuals when taking 4,759 or 2,675 steps/day, respectively. The reduction in plasma 
TG concentration may be due to an increased uptake by tissue and increased oxidation, 
which was also significantly increased in NORM compared to the other trials.  
This is a striking difference as reductions in TG AUCI after similar exercise has 
been shown to induce TG AUCI reductions on the order of 20-40%, compared to a non-
exercise control (46, 99, 183, 221). In other words, when taking 8480 steps/day (i.e.; 
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NORM), the observed reductions in TG AUCI, compared to both of the LOW and LIM 
trials, were similar to reductions typically seen compared to a “no exercise” condition. 
Despite completing identical exercise bouts, the night before commencement of the HFTT, 
participants seem to have displayed decreased responsiveness to said exercise if they 
reduced daily steps below ~4,700 steps/day; at least in regards to PPL. Olsen et al (145) 
found simply reducing steps from ~10,500 to ~1,400 steps/day for two weeks increased 
TG AUCT by 21% in the absence of exercise.  
Recent research has begun to place a particular emphasis on the benefits of 
increases in daily step counts (107, 111, 189, 191). This is probably due to the ease of 
translation as a step/day metric is easy to understand and practical, thanks to technology 
such as wearables that increase the ease of self-monitoring effectively and affordably. 
Some have recently proposed an inverse dose-response between daily step counts and 
incidence of cardiovascular disease, type 2 diabetes, and all-cause mortality (107) (111).  
Lee et al. (111) found rates of mortality progressively declined with increasing daily steps 
until plateauing at approximately 7,500 steps/day. Contrary to the findings in the present 
study, the authors reported groups taking as few at 4,363 steps/day displayed reduced 
mortality compared those taking 2,718 step/day. The difference in findings may be due to 
the fact that the participants in Lee et al. were substantially older than the population 
recruited for the current study.  Moreover, a recent meta-analysis (107) suggested a 10% 
reduced risk of cardiovascular events for each 2,000 step increase in daily step number up 
to 10,000 steps/day.  These investigations differ from the findings in this study, as we did 
not find any improvement in postprandial responses when an individual increased daily 
walking from ~ 2,700 to ~ 4,750 steps/day. A few important distinctions should be noted 
and may explain this discrepancy. First, and most obviously, the current investigation 
focused on responses following moderate exercise which was not employed in the 
 52 
aforementioned studies. Secondly, the “baseline” step counts in almost all of these 
investigations, and given as a hypothetical baseline within one (107), exceeded 5,000 
steps/day (107, 111, 216) which excludes comparisons below this level of daily walking, 
such as the 2675 step/day trial presented herein. The current investigation was also 
conducted over a much shorter time period than the observations.  Lastly PPL, while 
indicative of CVD events, is only a single factor contributing to the development of CVD 
and should not be considered equivalent or wholly indicative of CVD. 
It is possible that at severely reduced step counts (<5,000 steps/day) physiological 
and metabolic responses differ from those above ~8,000 steps/day. This seems to be 
buttressed by a growing public health literature that suggest a daily step count at or below 
5,000 should be classified as a “sedentary lifestyle index” (189, 191) and should be viewed 
as a problematic because of the distinct health ramifications seen below this level of 
activity due to “non-exercise activity deficiency” (64). Though this is a reduction below 
the level some would consider ‘normal’, it should not be ignored. In fact estimates from 
the NHANES study, based on objectively collected accelerometer data, indicate 
approximately 37% of the US population would fall below this level of daily activity (194).  
Our findings are particularly interesting in light of recent findings of a phenomenon 
termed “exercise resistance” (1, 98). These authors observed individuals taking less than 
4,000 daily steps were resistant to the exercise stimulus provided by 1-h of running at ~65% 
VO2max. In these randomized crossover trials (1, 38, 98) the protective effects of exercise, 
preventing exaggerated rises in postprandial plasma triglycerides and glucose, were not 
realized if daily step counts were reduced by imposed sitting of 13 hours or more. It seems 
by drastically reducing the contractile activity in the study participants, an environment 
was produced within the muscle that prevented the classic improved response to the 
exercise stimulus. It has been postulated in a recent meta-analysis by Ekelund et al (39) 
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that individuals experiencing high levels of daily inactivity are at an increased risk of 
mortality even when participating in similar levels of daily activity (e.g. MET hours). 
Taken together it seems that reduced contractile activity causes a condition in which current 
exercise recommendations may not be enough to derive protective benefits. Thus a higher 
minimum level of recommended physical activity may be needed for populations regularly 
experiencing prolonged inactivity.  
Muscle lipoprotein lipase (LPL) is the rate limiting enzyme for clearance of plasma 
triglycerides (202). Therefore, decreased LPL activity is a rational candidate for explaining 
the increased PPL found in this study with LOW and LIM. Although not measured directly 
in the present investigation, low levels of contractile activity have been observed to 
drastically reduce the activity in LPL in muscle.  In an animal model, hind-limb 
immobilization has been shown to have sizeable reductions (i.e. 90% decrease) in LPL 
activity and developed rapidly (>60% reduction in <12h) (15). However, it seems the 
downregulation is post-transcriptional. Even in the tissue with more than 90% reduction in 
LPL activity, LPL mRNA was similar to baseline (15). Additionally, the data from this 
study (15) indicate LPL mRNA is not increased with walking or levels of contractile 
activity associated with maximal increases in LPL activity. It seems LPL activity may be 
down regulated by GPIHBP1 protein endocytosis induced by some co-factor produced 
during periods of prolonged inactivity (12, 94). However, this hypothesis was not tested in 
the present study and needs additional investigation to fully elucidate a mechanism. 
It is plausible that this study would have a greater impact if it were conducted in an 
older population. This is due to the increased magnitude and duration of the postprandial 
triglyceride elevation in older populations, compared with their younger counterparts (11, 
62). Postprandial TG concentrations have been observed to peak 2-3 hrs earlier in young 
people while aged participants showed increased rates of chylomicron accumulation 
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peaking at concentrations nearly four-fold greater (141). The durations of these elevations 
above baseline mirrored these findings, returning to baseline after 6 hours in the young 
compared to 24 hours in an older population (11). However, it has been postulated that this 
increased PPL is due to the decreases in non-exercise activity associated with aging (62). 
Moreover, technological advances have drastically decreased occupational physical 
activity such that activity in much of the workforce can approximate that of sedentary, 
elderly individuals (26). This is not obviated completely even in health-conscious 
individuals. For example, ‘workday’ sedentary time in 208 marathon and half-marathon 
participants was observed to be similar to those seen in the elderly in assisted living 
communities (90, 206). Thus, this work addresses a population that may still be at 
significant health risk. 
In conclusion, to the best of our knowledge the current investigation is the first to 
indicate that 2 days of step reduction can decrease an individual’s responsiveness to an 
acute aerobic exercise bout in terms of stimulating improved PPL and fat oxidation.  When 
participants took 8,480 daily steps and performed a 1h bout of exercise, their responses in 
TG excursions and AUCs were significantly lower than following the same exercise with 
step counts at 2,675 and 4,759 steps/day. When viewed from the perspective of previous 
literature, the reduction in TG AUCI when participants took 8,480 steps, compared to either 
of the lower daily step counts in this study, were similar to expected reductions that have 
been observed to occur in  a non-exercise control (46). This may support the exercise 
resistance phenomenon recently coined by Kim et al (98), in which individuals who spend 
the majority of their day sitting and take relatively few steps are unable to reap the benefits 
generally associated with acute aerobic exercise (39, 124). Based on these data, from the 
current investigation and others, it seems that reducing daily steps may cause development 
of a condition in which the inactive muscle demonstrates blunted responses to normal, 
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healthy stimuli. Recent observations support this contention in that not only PPL is 
impaired but reduced myofibrillar protein synthesis can be seen in elderly (22) and young 
healthy individuals (166) in response to step reductions to ~1400 steps/day of two weeks 
or less. These findings coupled with previous work on exercise resistance (1, 38, 98) 
emphasize the necessity of maintaining a sufficient amount of physical activity (i.e.; >8,500 





Tables and Figures 
 
 
Figure 7. Study Design. Participants completed a five-day randomized, crossover 
experimental design with differing levels of daily step reduction (i.e. Low- 2,675, 
Limited- 4,759, & Normal Activity-8,480 Steps/Day). Participants completed two control 
days with activity monitoring before the initiation the two-day step reduction (D1 & D2). 
Participants also completed an hour of treadmill running on the night of D2 followed by 







Figure 8. Total and Incremental areas under the curve of plasma triglyceride 
concentrations during HFTT for each trial. (*) significantly different from Low & 
Limited step group, p<0.05. (†) significantly different from Low step group, p<0.01. Data 


























































Figure 9. Total and Incremental areas under the curve of plasma glucose concentrations 
















































Figure 10. Temporal Responses of plasma triglyceride concentrations for each trial 
during HFTT. (*) Normal significantly different from Low, p<0.05. (†) Normal 
significantly different from Limited, p<0.05. (#) Normal significantly different from 

































Figure 11. Temporal Responses of plasma glucose concentrations for each trial during 
HFTT. Data reported as meanSE. 
 
  































Table 4. Descriptive statistics for participants at the beginning of the study. All data 
reported as mean  SE. 
  
Physical Characteristics mean  SE 
Age (y) 23.4  5 
Height (cm) 166.4  7.9 
Body Mass (kg) 74.4  16.9 
BMI (kg·m-2) 26.7  5.2 
Note: Data are presented as MSE 
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  Exercise Responses mean  SE 
Maximal Oxygen Consumption  
 VO2max Absolute (ml/min) 3,405  242 
 VO2max Relative (ml/kg/min) 42.7  1.4 
Submaximal Exercise During 1-h Run  
 Heart Rate (bpm) 154  4 
 Rating of Perceived Exertion 11.4  1.1 
 VO2 (ml/min) 2210  154 
 % VO2max  64.4  0.4 
 Treadmill Speed (mph) 4.8  0.2 
Note: Data are presented as MSE  
 
Table 5. Responses to maximal exercise and the 1-h bout of submaximal exercise. 




Day of Trial 
 C1 C2 D1 D2 
Daily Steps 
Low 10198  1476 11015  1159 2744  331 2605  313 
Limited 9808  1207 10568 1112 4482  318* 5037  206** 
Normal 11056  1324 10732  936 8431  732† 8530  420† 
Note: Data are presented as MSE. (*) Significantly different from Low, p<0.05. (**) Significantly different from Low, p<0.01.     
(†) Significantly different from both Low & Limited, p<0.01 
Table 6. Average daily steps measured via activPal activity monitor, attached on the 
participant’s anterior thigh throughout each trial. Average daily step counts for each trial 
are presented for Control (C1 & C2) and Intervention Phases (D1 & D2). (*) significantly 
different from Low, p<0.05. (**) significantly different from Low, p<0.01. (†) 





Postprandial Time (Hours) 
Baseline H2 H3 H4 H6 
Triglyceride Concentration (mg/dl)      
 Low 89.8  7.5 147.5  13.5 172.4  13.0 176.5  16.2 133.0  13.6 
 Limited 81.1  9.1* 134.0  11.1 175.4  15.5 167.6  16.3 126.2  14.2 
 Normal 80.0  5.8 125.3  9.8* 151.3  11.3*†   141.6  11.9*† 115.7  12.2 
Glucose Concentration (mg/dl)      
 Low 91.8  4.3 116.4  6.7 --- 139.7  16.8 116.3  10.4 
 Limited 92.5  3.4 115.4  5.7 --- 122.7  10.6 110.1  5.4 
 Normal 94.5  3.7 108.2  4.4 --- 130.4  7.3 111.4  6.2 
 
 
Table 7. Hourly responses (e.g.; H2, H3, etc.)  of plasma triglyceride and plasma glucose 
concentrations during HFTT for each trial. (*) Significantly different from Low, p<0.05. 




Treatment Group  
Low Limited Normal 
RER 0.81  0.01 0.80  0.01 0.77  0.01* 
Fat Oxidation (%) 66.1  4.87 69.6  3.93 80.4  2.65* 
Fat Oxidation (kcal/6h) 318.9  34.5 342.4  30.9 396.0  27.5* 
Carbohydrate Oxidation (%) 33.9  4.87 30.4  3.93 19.6  2.65* 
Carbohydrate Oxidation (kcal/6h) 164.0  25.3 149.0  24.1 97.8  12.8* 
Total Energy Expenditure (kcal/6h) 482.9  32.6 491.4  31.2 493.8  27.0 
 
Table 8. Overall postprandial substrate oxidation during HFTT for each trial. (*) 




Chapter VI:  General Summary 
These studies were conducted in order to determine: 1) if the background level of 
daily physical inactivity impairs postprandial lipemia (PPL) and cardiovascular adaptations 
to short term training and 2) the effect of altering daily step counts for two days on the 
ability of a 1-h bout of moderate-intensity exercise to reduce PPL.  
In Study 1, it was shown that inducing physical inactivity by reducing daily step 
count to 4,767 steps over 11 days, in conjunction with vigorous-intensity exercise training, 
resulted in an inability to incur the classic PPL-lowering effect of acute exercise as well as 
short term training. Furthermore, classic adaptations, such as decreases in heart rate and 
blood lactate concentration and increases in muscle oxygenation and fat oxidation when 
exercising at an absolute workrate, typically seen with exercise training and displayed in 
the High Step group (p<0.05), were not significant in the Low Step group. This is consistent 
with the findings of Kim et al. (98) that first coined the term ‘exercise resistance’, but also 
extends this phenomenon to an impairment of short-term training adaptations as well as 
measures of postprandial metabolism. These data indicate that, even in individuals who 
participate in the early stages of regular exercise training, background inactivity results in 
elevated PPL and impaired cardiometabolic adaptations to short term training. 
In Study 2, it was demonstrated that reducing daily steps to 4,759 or below is 
associated with a decreased ability of acute exercise to lower PPL, compared to a trial 
taking 8,480 steps/day. Responses to a high fat meal on the morning following a 1-h run at 
64% of VO2max were similar in groups taking 2,675 (LOW) and 4,759 steps/day (LIM). 
However, following an identical exercise bout, participants taking 8,480 steps/day 
(Normal) significantly reduced their plasma triglyceride incremental area under the curve 
compared to LOW and LIM trials (p<0.05). This indicates that the development of the 
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aforementioned ‘exercise resistance’ occurs when steps/day drop below approximately 
5,000. These findings suggest that some beneficial effects of acute exercise can be 
diminished if individuals experience regular periods of inactivity leading to reduced daily 
steps (i.e. below approximately 5,000 steps/day). 
Taken together, these studies suggest deleterious effects of inactivity on an 
individual’s ability to properly respond in terms of cardiometabolic adaptations (i.e; PPL, 
HR, lactic acid, fat oxidation and muscle oxygenation) to an exercise stimulus provided by 
1-h of running or 9 days of chronic training. The Low Step treatment group in study 1 took 
approximately 5,000 steps/day which is similar to the limited step trial (LIM) in study 2. 
This is useful in comparing the effects of reduced step counts in both studies. Taking 
~5,000 steps/day seems to have rendered the exercise training ineffective in lowering PPL 
in study 1 in that postprandial responses following training were not significantly different 
from baseline responses. Additionally, data from study 2 shows acute exercise while taking 
~5,000 steps/day or less (i.e. LIM & LOW trials) is less effective at lowering PPL 
compared to taking ~8,400 steps/day. Jointly the findings in this dissertation suggest that 
< 5,000 steps/day is insufficient to realize the protective effects of acute or short term 
exercise training, at least in terms of PPL and fat oxidation (Table 9). The exercise 
resistance phenomenon first postulated by Kim (1) seems to manifest itself when taking 
less than 5,000 steps/day, regardless if the exercise is of moderate or vigorous intensity and 
persists even with regular, short-term training.  It should be realized however, that although 
taking less than 5,000 steps/day appear ineffective in preventing exercise resistance, and 
taking approximately 8,500 steps/day is effective, it is still unclear how activity levels 
between these step counts affects the development of this phenomenon. 
These findings suggest that reductions in daily step counts are associated with 
impaired cardio-metabolic responses (i.e.; postprandial lipemia and fat oxidation) to both 
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acute and short term exercise training. These studies have some noteworthy strengths in 
that they add pertinent information to the literature especially surrounding the newfound 
“exercise resistance” phenomenon. To the authors knowledge this is the first study to 
consider the interplay of physical inactivity and short-term training. Moreover, the second 
study provides important information on hoe to characterize the onset of this new 
phenomenon. Lastly, these findings suggest that even young, healthy individuals are 
susceptible to negative cardio-metabolic effects of physical inactivity that cannot be easily  






Study 1 (Training) HIGH STEP LOW STEP  
Steps per Day 16,048 4,767*  
    
Study 2 (Acute) NORMAL LIMITED LOW 
Steps per Day 8,431 4,759 * 2,744* 
    
Table 9. Summary of findings (*) signifies impaired metabolism 
  
 69 
Chapter VII:  Review of Literature 
Introduction 
 
The perils of physical inactivity have been generally appreciated for several 
millennia. Susruta, an Indian physician in the 7th century BC, may have been the first 
physician to prescribe daily activity. He believed daily physical activity was necessary to 
ward-off disease, even stating “diseases fly from the presence” of such individuals 
participating in habitual physical activity (177). Not long after in the 5th century BC, 
Hippocrates is quoted as saying “walking is man’s best medicine” and, “all parts of the 
body… if they are unused and left idle, become liable to disease…” (106). Moreover, the 
effects of physical inactivity have been observed and studied systematically since the 
1950’s. The seminal work by Morris et al. (133) found an increased rate of coronary 
artery disease in London bus drivers compared with their more active counterparts on the 
busses, the conductors. These findings suggest that individuals who are chronically 
inactive can suffer serious detriments to health as a result. Since then, numerous studies 
have been conducted to evaluate the deleterious effects of physical inactivity. However, 
even with the recent interest and the emergence of the field of inactivity physiology (63), 
it seems we have only scratched the surface in understanding the harmful effects of 
inactivity and its increasing prevalence in many modern cultures.  
In modern culture we are continually engineering activity out of our daily lives. 
As such, periods of prolonged inactivity have become routine in the lives of many. This 
is especially prevalent in well-developed countries in which technological advances allow 
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for increased automation and vehicular transportation (217). The populations of such 
societies also rarely go more than 8 hours without eating. Consequently, these individuals 
spend most of their time in a non-fasting or postprandial state. As a consequence of an 
increasingly sedentary lifestyle, periods of prolonged sitting and the postprandial state 
routinely coincide resulting in chronically elevated levels of plasma triglyceride and 
glucose. The consequences of prolonged sitting have begun to be recognized by some 
countries who have already made a conscious effort to advise against prolonged bouts of 
sitting (217). In the postprandial state, triglyceride levels in the plasma can remain 
elevated for up to 10 hours, typically peaking 3 - 6 hours after a meal rich in fat (152). 
The magnitude and duration of this elevation is influenced by prior physical activity (52, 
120, 221), diet (174), and genetics (173, 204). As demonstrated in recent epidemiological 
studies (5, 142), non-fasting plasma triglyceride levels, i.e., post-prandial lipemia (PPL), 
better predicts cardiovascular events than fasting plasma triglyceride levels and are 
known to be associated with diseases, including metabolic syndrome, type 2 diabetes, and 
atherosclerosis. 
In several other recent epidemiological studies, sitting time has been strongly 
linked with the risk of obesity, metabolic disorders including type 2 diabetes mellitus and 
especially with cardiovascular disease and death (16, 198). Exercise as an intervention 
has been studied with promising results (76, 120, 222). However, recent epidemiological 
studies have reported that the risks from prolonged sitting appears “independent” of the 
volume of exercise being performed (16, 150, 198). This means individuals who meet the 
recommended guidelines (AHA or ACSM) for physical activity of 150 min/week of 
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moderate intensity exercise appear to still be at risk for developing cardiovascular disease 
if they have a lifestyle routinely incorporating prolonged periods of sitting (>10-12 h/day) 
(39). In 2016, the term ‘exercise resistance’ was first introduced to describe a 
phenomenon in which individuals who experience prolonged periods of inactivity seem 
unable to realize some of classic metabolic benefits associated with an acute bout of 
aerobic exercise (98).  
 
Postprandial Metabolism and Health 
 
In order to best analyze the effects of physical inactivity on health, it is necessary 
to establish a measure that can serve as a proxy for cardiometabolic health and is 
sensitive to the changes associated with inactivity. The method that seems to be the most 
promising is the measurement of blood lipids, in both the fasted and non-fasted state. 
Much is understood about the dangers linked to elevated fasting plasma triglyceride 
levels (79, 121). However, recent epidemiological and scientific evidence suggests 
postprandial lipemia (PPL) is a stronger indicator of CVD risk than is fasting plasma 
triglyceride level (5, 87, 88, 142).  
Chronic dyslipidemia and the oft-resultant atherosclerosis are two of the principal 
contributors to CVD (87, 207, 223, 224). Within first-world countries, where food is 
plentiful, a significant amount of time is spent in the postprandial state, leading to longer 
periods of elevated triglycerides. These increased PPL levels are associated with reduced 
high-density lipoprotein production and increased low-density lipoprotein cholesterol 
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production (44), impaired endothelial function (199), and increased atherosclerotic 
plaque formation (223). 
There are two major sources of circulating triglycerides. These can be produced 
from an endogenous pathway within the liver (e.g. lipogenesis) or can be consumed 
through exogenous dietary sources (73). Dietary consumption can lead to two different 
ultimate destinations of exogenous lipids, depending upon their type. Short-to-medium 
chain fatty acids are transported primarily to the liver, then successively to their final 
destination, often being skeletal muscle, undergoing beta oxidation to aid in successfully 
supplying the energy needs of the tissue. However, triglycerides composed of long chain 
fatty acids, are carried predominantly via chylomicrons and/or very low-density 
lipoproteins (VLDL), and transported to adipose and  muscle tissues (144). The main 
transporter of endogenous lipid production are VLDLs. Conversely, for ingested 
triglycerides, chylomicrons are the primary vehicle (56, 140). Chylomicrons are formed 
in the endoplasmic reticulum of small intestine enterocytes and are secreted into the 
lymphatic system. Subsequently chylomicrons travel through the lyphatic system and 
enter systemic circulation via vena cava (86).  In the postprandial state, the formation of 
chylomicrons may compete with lipoproteins to interact with lipoprotein lipase (LPL), an 
enzyme located on the luminal side of vascular endothelial cells in adipose, skeletal 
muscle, and myocardial tissue (18, 32, 201). LPL hydrolyzes the triglycerides from both 
VLDL and chylomicron sources. However, after a meal as the chylomicrons 
concentration increases, VLDL production continues as it is modified by liver 
concentrations of FFAs. The result is a level of circulating triglycerides and cholesterols 
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that is elevated significantly (223). As chylomicrons and VLDLs both utilize LPL as an 
uptake mechanism, postprandial saturation of LPL can occur as the two molecules 
compete for binding sites (32, 201). Therefore, this increase in circulating 
cholesterol/triglycerides and concomitant saturation of LPL allows for the opportunity for 
chylomicron and VLDL byproducts to build up in the subendothelial space. During 
instances where dietary consumption leads to an increase in PPL.  Furthermore, residual 
fatty acids from chylomicron hydrolysis may be re-esterified in the liver as VLDL and 
eventually used to synthesize various byproducts, including low-density lipoproteins 
(LDL) (55, 87). It is this production and accumulation of LDL, and other VLDL 
remnants which is the genesis of atherosclerosis (59, 223, 224).  
Atherosclerosis has numerous sources that contribute to its development including 
endothelial dysfunction (3, 33) and abnormal blood lipids (134, 142, 223). The most 
common explanation for the onset of atherosclerotic formation begins with an increased 
accumulation of lipoprotein behind the endothelial wall of the vasculature (117, 138, 
209).  Here these lipoproteins undergo modification through oxidation, lipolysis, 
proteolysis, and aggregation. Eventually fostering the formation of foam cells via 
macrophage infiltration/conversion and to inflammation of the surrounding tissue (117, 
172). The resulting damage is eventually repaired but leaves behind underlying tissue 
which may begin to form a necrotic core and exterior calcification. This tissue is then 
vulnerable to later injury which may cause release of the interior contents of the lesion 
and can lead to thrombosis (117, 171). This thrombosis is a likely cause of cardiovascular 
events such as stroke or myocardial infarction.  
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Prevalence of Inactivity in Modern Culture 
 
The magnitude and consequences of physical inactivity in modern times have led 
to it being appropriately termed a global pandemic (105). In order to understand the 
prevalence of inactivity in a modern lifestyle, it is important first to define the terms by 
which one would be considered inactive. In 1995 the Centers for Disease Control and 
Prevention (CDC) and American College of Sports Medicine (ACSM) published 
minimum recommendations prescribing 30 minutes of moderate intensity exercise on 
most, preferably all, days of the week (149). These guidelines were recently updated with 
additional support for beneficial effects of physical activity and the removal of a 10-
minute minimum duration for activity (157). This level of physical activity equates to 
about two miles of brisk walking, accumulated throughout the waking hours of an 
individual’s day. Physical inactivity is generally defined as failing to meet these 
requirements. Specifically, failure to achieve 150 minutes of weekly moderate to 
vigorous physical activity (MVPA), 75 min of vigorous physical activity, or a combined 
equivalent achieving 600 metabolic equivalent (MET)-minutes per week (208, 213, 214). 
Based on accelerometer data from the National Health and Nutrition Examination 
Survey, the prevalence of meeting these guidelines could be as low as 5% in the United 
States (182). Other more hopeful, yet still concerning estimates put this number at about 
31% meeting guidelines (60). 
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It is necessary to understand why this number is so low. Much of the increase in 
inactivity can be linked to modernization of the culture and the technology associated 
with said modernization. As societies continue to advance, technology must improve in 
order that the time spent in menial tasks can be better invested in more meaningful 
pursuits which spur further progress. However, it seems rather than current technology 
providing time savings that can be reinvested in other activities, it is instead being 
replaced by inactive behaviors causing a dramatic rise in daily inactivity.   
For example, estimates of daily step numbers indicate the introduction of powered 
machinery has causes a decrease of 50-70% of daily activity (19, 20, 143). Even in 
modern times populations, such as some Amish communities, who limit or completely 
abstain from the use of many modern technological conveniences take four times more 
daily steps as those who do not (9, 10). This is bolstered by observations like the 2017 
American Time Use Survey which revealed just over 5% of leisure time is spent in 
“exercise, sports, and recreation” (196). It seems that the lives of many are dominated by 
sedentary actives such as prolonged sitting. Some have suggested it is possible, if not 
likely, that 95-97% of an individual’s waking hours could be spent in sedentary activities  
(72, 205). Sedentary activities are defined as activities that involve energy expenditure at 
the level of 1.0-1.5 metabolic equivalent units (METs)(148). More tangibly, sedentary 
behavior includes activities that do not increase energy expenditure markedly above the 
resting level. Such as sleeping, sitting, lying down, and watching television. While 
exercise is prescribed broadly, a 30-minute daily session still allows for upwards of 16 
hours of inactivity. Further, evidence suggests that there may be no difference in sitting 
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time between those who achieve recommended levels of physical activity and those who 
do not (30). 
Engagement in light-intensity activity may be the best way to reduce sedentary 
behaviors.  One of the strongest negative correlations (r=-0.98)(71) in relation to 
sedentary time is time in light physical activity, such as walking, which involves energy 
expenditure at the level of 1.6-2.9 METs. (65, 139, 148). While the energy expenditure 
may only be slightly above that of sitting, these activities are the predominant 
determinant of overall daily energy expenditure - even in those who exercise regularly 
(34). Unfortunately, modern cultures fall short on this score as well. Tudor-Locke et al. 
(194) provides data suggesting 17% of US adults take fewer than 2,500 steps per day. 
Further about 37% take fewer than 5,000 steps, with anything under this level being 
considered by most to be indicative of a very inactive or sedentary lifestyle (163, 191, 
194). A decrease of 2,500 steps/day is associated with increases in sitting time on the 
order of 37-45 mins/day (191) or as much as 75 minutes (128). 
Another area that has seen a dramatic rise in inactivity is occupational time. (26, 
101). Nearly half of occupations in the 1960s could be characterized as requiring 
moderate activity. That number had dropped to less than 20% by 2008 and this trend is 
expected to continue (26). These authors concluded that the decrease from occupational 
energy expenditure over 4 decades could almost entirely explain the increase in weight 
seen in the NHANES study over the same period (26). This trend effects even those who 
are most active. Data from one study (206), more clearly illustrates this alarming point. In 
this study, marathon and half marathon participants who, by the nature of their 
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recreational choices, are presumably very active were found to have daily sitting times 
roughly equivalent to those found in elderly community-dwelling populations during the 
work week (90, 206). 
 
Deleterious Effects of Inactivity 
 
The prevalence of inactivity is extremely concerning, especially given the effects 
on the health of millions. While the health hazards do not command the same attention 
from governments and health organizations, the deleterious effects of inactivity are 
similar to, if not greater than, those seen with smoking and obesity (112). The impact of 
these on an individual health can be more hazardous but, the prevalence of inactivity is 
much higher than either smoking or obesity, leading to an effect on the population that is 
no doubt more severe. In 2009, physical inactivity was officially recognized as the fourth 
independent risk factor for non-communicable diseases and accounted for more than 5 
million preventable deaths per year (112, 213). 
It is estimated that 20% of all CVD and 10% of strokes occur due to physical 
inactivity (35) and over 30% of ischemic heart diseases (105). According to data 
published in The Lancet, inactivity is a causal factor in 9% of premature mortality (112). 
Further, a reduction in the prevalence of inactivity by just 25% worldwide would prevent 
over 1.3 million deaths each year (112).  Well-reasoned estimates contend that if every 
person in the United States were to meet physical activity guidelines nationwide, life 
expectancy would increase by at least 0.68 years on global life expectancy (112). This 
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number may seem low, as discussed by the authors, but when viewed in the proper light it 
is actually substantial.  That is, those who are already sufficiently active would see no 
increase in life expectancy, therefore inactive individuals under this estimate could see an 
increase of four or more years in life expectancy. 
One of the starkest examples illustrating the potency of inactivity to cause 
deleterious health outcomes is the classic Dallas Bed Rest Study. In this study, trained 
participants underwent 20 days of bed rest. This intervention induced reductions of over 
25% in VO2max, cardiac output, and stroke volume and an 11% decline in total heart 
volume (162). In a follow-up study, McGuire et al. found that these decrements were 
greater than the decline in these variable resulting from 30 years of aging (125). Given 
the inverse relationship between cardiorespiratory fitness and all-cause mortality (103) it 
is clear that inactivity, at least with respect to this level of inactivity, is particularly 
unhealthy. 
  It is important to understand why these concerns are especially pertinent to first 
world countries like the US in which heart disease is the number one cause of death 
(102). CVD and premature mortality seem to be strongly linked and show a direct dose 
response relationship to physical inactivity (39, 104). Therefore, several other models of 
inactivity have been employed in studying the deleterious effects that lead to these health 
outcomes.  Dunstan et al (2004) observed that, when comparing TV time, those who 
spent the most time watching television were more likely to have diabetes. Additionally, 
when comparing those with the most TV time to group with the least reported time, 
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women were more likely to have compromised glucose tolerance. These results held even 
after adjusting for total time in physical activity as well as other covariates (37). Another 
analysis of prospective data (84), found a significant trend for increasing obesity and 
Type II diabetes risk across categories of increasing TV viewing time. Again, this trend 
remained significant after adjusting for covariates including a measure of exercise 
participation. Katzmarzyk, et al. (93) provided data from a prospective study of physical 
activity, sitting time and mortality. These data revealed a significant dose-response 
relationship between sitting time and both all-cause and cardiovascular disease mortality. 
Intriguingly, When participants were stratified by activity this dose-response relationship 
was slightly attenuated, but persisted even among those meeting PA guidelines (93) 
Due to these and other similar revelations, a new field of inactivity physiology was born. 
The main contention of this field is that inactivity is harmful in that it not only impacts 
typical exercise induced health benefits but prompt a set of completely divergent health 
implications that arise not from the lack of exercise but from the effects of inactivity (64, 
147). 
 
Exercise and Postprandial Metabolism 
 
Physical inactivity has been recognized as a major independent risk factor in the 
development of CVD (28). Thus, it stands to reason that one remedy for the rise of CVD 
in modern culture would be engaging in regular exercise. Exercise is universally 
recognized to decrease the risk of a variety of chronic diseases and metabolic disorders 
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(154). Exercise training has been shown to reduce risk of atherosclerotic plaque 
formation associated with excessive blood lipid concentrations (43),which leads to lower 
cardiovascular disease (CVD) risk in individuals who are physically active compared to 
inactive individuals (14). More specifically, a single bout of exercise can have impact on 
PPL by affecting circulating triglyceride levels following a meal (46, 76, 120, 168, 222). 
Studies using an intravenous lipid tolerance test indicate that the protective effect of an 
intense bout of exercise is attributed to accelerated TG clearance from the circulation 
(165)  
This effect of exercise is fairly robust. Prior exercise attenuates PPL when a meal 
is given several hours after exercise (i.e.12 h) regardless of whether the meal is of 
moderate or high fat (85), or exercise is of low, moderate, or high intensity (129, 183, 
186) and even in response to resistance exercise (186, 219). There are several variables 
that can influence the exerted effects of exercise such as timing of exercise, intensity, and 
energy balance as well as the composition of the test meal. 
Timing of the exercise seems to be an important factor in assessing this effect. It 
is important to understand when a bout of exercise begins to exert a sizable effect on 
postprandial metabolism and when that effect subsides. Once these are correctly 
understood, it becomes easier to sustain healthy plasma triglyceride levels and ward off 
atherosclerosis and associated CVD.  
It seems that the delayed effect (>12h) of exercise on PPL is more robust than the 
acute effect (222). When test meals are given immediately following exercise or closely 
there after (<4h) some mixed results have been reported (124). During this time many 
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factors can confound the effect of exercise such as the flux in fasting triglyceride levels 
from the resultant increase in lipolysis and subsequent increase in free fatty acid (FFA) 
delivery to the liver (175). Some of these studies show discernable difference in PPL in 
response to a high-fat meal, but these differences could not be seen if a moderately-fat 
test meal was employed (155, 158). The lack of a difference persists in cases where either 
moderate or low intensity exercise was undertaken (155, 156). Also during this time, 
very-low intensity (25-30% VO2max) and resistance exercise have shown no effect, or 
even adverse effects on PPL (23, 92).  
 Conversely, when a test meal is given 12-16 hours after an exercise bout the 
effects are much more ubiquitous on PPL. The effectiveness of exercise is apparent over 
a vast range of intensities from 25-90% of maximal oxygen uptake (VO2max), and 
durations of exercise ranging 30-120 minutes (52, 76, 120, 130, 168, 183, 222). This is 
also true regarding the mode and type of exercise. As previously mentioned, aerobic and 
resistance training both show clearly discernable benefits on PPL. High intensity interval 
training (HIIT) has also been employed and seems to show an even greater ability to 
attenuate PPL (47, 183)  
 However, this attenuation does not continue indefinitely. Data suggest this effect 
of acute exercise is transient in nature and may only continue to show appreciable effects 
on PPL for 24-40 hours (76, 124, 187). It seems that while this attenuated PPL response 
is still distinct from non-exercising controls up to 42 hours post exercise, (75, 76) but this 
difference is no longer apparent after 60 hours (76, 77). Therefore despite evidence that 
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active middle-aged men have lower plasma triglyceride concentrations than their 
sedentary counterparts, both fasting (83) and in response to a high-fat meal (164), this 
training provides no protective effect after the transient effects of the last bout subsides in 
42-60 h. This has been seen in investigations ranging from 1 week of training to 6 
months. After one week of training investigators report improved postprandial 
metabolism in the absence of any other metabolic changes, suggesting the improvements 
are a transient and induced by activity in the final bout of exercise (159). When 
participants are asked to abstain from exercise for 60 h prior to measuring PPL, the 
difference between active (endurance and sprint/strength trained) and inactive 
counterparts is abolished (185). Interventional studies have shown that one month of 
aerobic training appears ineffective in positively influencing PPL, when it is measured 2 
(53, 169), 2.5 (77), or 9 days (7) after detraining.  
Intensity is also an important factor in modulating this PPL response. A bout of 
high intensity interval aerobic exercise or resistance exercise may reduce fasting plasma 
triglycerides the next day in a similar magnitude and via a similar mechanism as 
moderate intensity aerobic exercise of almost twice the energy expenditure (24, 67). 
Furthermore, HIIT training has been shown to induce a larger reduction in the 
incremental area under the curve (iAUC) response than aerobic (46, 184). Freese et al. 
(47) found that an accumulation of 18 minutes of HIIT could induce an attenuation of 
PPL similar to continuous aerobic exercise lasting 30 minutes or longer. Further these 
authors compared 30 minutes of brisk walking to five, 30 second maximal sprints with 4 
minutes of rest and found that only the HIIT sprints caused a reduction in PPL 
 83 
incremental AUC (48). Some contend that this method is flawed in the inability to 
accurately account for total energy expenditure because of the anaerobic component of 
this type of exercise and subsequent increase post-exercise oxygen consumption (46). 
However, when Trombold et al. (183) compared 2 min intervals at 90% of VO2peak to 1 
hour of continuous exercise at 50% of VO2peak resulting in the same energy expenditure, 
these investigators found the intervals significantly reduced PPL compared to control and 
continuous exercise. The results indicated HIIT exercise was better at attenuating PPL, as 
the investigators found a significantly reduced triglyceride incremental AUC when 
compared to the continuous exercise and non-exercise groups (183). Nevertheless, the 
same group produced data indicating that intensities as low as 25% VO2max still 
produced significant differences in PPL compared with controls (99). Cumulatively these 
data suggest that while a large range of intensities can be employed to combat PPL, 
increased intensities do, in fact, result in more effective and potent reductions. 
It has been suggested that this most crucial variable in permitting an attenuation 
of PPL is not the intensity or duration of exercise but the existence of an energy deficit 
resulting from the exercise undertaken (8, 46, 124, 129, 178). Under this premise, Gill 
and Hardman (52) investigated energy deficits induced by exercise and reduced caloric 
intake. They found caloric restriction produced positive results but the deficit imposed 
via exercise was superior at reducing PPL compared with equivalent deficits resulting 
from caloric restriction. However, aerobic exercise has been shown to lower plasma 
triglyceride concentrations in the absence of concomitant energy deficit (2). Tolfrey et al. 
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(179) found that high intensity cycling can reduce PPL, even when energy expenditure is 
replaced. However, a still greater effect existed in a group which remained hypocaloric, 
suggesting an interaction. 
One prevailing hypothesis suggests that the mechanism by which these exercise-
induced improvements in postprandial metabolism are achieved is via an increase in 
lipoprotein lipase (LPL) activity within the active skeletal muscle (46, 124). This is 
supported by studies suggesting the exercise-induced attenuation of PPL cannot be 
attributed to acute exercise-induced changes in blood flow or energy stores (225). 
Skeletal muscle LPL, found on the vascular endothelium, is the main site of triglyceride 
removal, and the activity of LPL can be increased through exercise (58, 164, 165). It 
seems contractions of the skeletal muscle cause a transient (165), tissue specific (164) 
increase in skeletal muscle LPL enzyme activity. This increase in LPL activity, as well as 
protein, is a local, delayed response to contractile activity and is independent of 
catecholamine and other cardiometabolic responses to exercise (58). The exercise-
induced increase in LPL mRNA levels peaks 4 h after exercise, whereas LPL protein 
peaks 8 h after exercise and returns to baseline values within 24 h post-exercise (97, 165). 
While exercise has a robust effect on LPL, inactivity may have an even greater effect. 
Over 90% of LPL activity typically present in skeletal muscle can be lost by preventing 
ambulatory activity, while light activity has been shown to increase LPL activity (15). In 
fact, Bey and Hamilton (15) reported that intensities roughly equivalent to casual walking 
could maximally activate LPL in slow muscle fibers. 
It seems that elevated plasma insulin concentrations can suppress LPL activity 
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(97). Three days of high carbohydrate (CHO) diet results in increased plasma insulin and 
55% lower LPL activity (89). Conversely, a low-CHO diet for the same duration results 
in an increase in LPL activity (115). This may serve to reconcile some of the spurious 
results found in previous research. Even if the same exercise was employed the 
carbohydrate content of the test meal could results in divergent responses. To address 
this, Trombold et al (184) used a high (83%) and low CHO (12.5%) test meal following 
identical exercise regimens. In this study, although both replaced the exercise-induced 
calorie deficit, only the group given the low-CHO test meal showed reductions in PPL. It 
stands to reason that an exaggerated rise in plasma insulin could cause a subsequent 
suppression of LPL activity in response to the high carbohydrate content of the test meal. 
Nevertheless, exercise-induced reductions in PPL have also been documented even in the 
absence of significant changes in plasma insulin or improvements in insulin sensitivity 
(54, 123, 129). 
 
Alterations in Ambulatory Activity  
 
It is well established in the current literature that regular physical activity, 
including exercise, is advantageous for those seeking to reduce risk of detrimental health 
outcomes (68). Exercise is different from physical activity by its purposive nature (25). 
While the dramatic effects of the various types and modes of exercise have dominated the 
literature, more recently the effects of changing regular non-exercise physical activity 
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have gained a greater appreciation and considered more frequently in interventional 
studies. 
Light intensity activity has an inverse linear relationship with a number of cardio-
metabolic markers and the impact of these activities as a biological stimulus contributing 
to better health has probably been significantly underestimated (36, 72). Much of this is 
attributed to the replacement of unhealthy behaviors with healthy ones. In fact, almost all 
variation in sedentary time across the population is related to the extent to which 
sedentary time is replaced by light intensity activity (36) 
One of the most attractive and practical interventions currently used in 
investigations of the effects of physical inactivity is reductions in daily step number. This 
is because reductions in daily steps are less extreme than bedrest, spaceflight, and other 
models of inactivity. Moreover, using easily accessible pedometers and accelerometers 
makes monitoring much less arduous and more replicable. Due to the tangible nature of a 
daily step number metric and the ability to employ these interventions under free-living 
conditions, the conclusions garnered from these studies are more readily applicable to a 
general population. This is also reasonable in view of growing epidemiological evidence 
that suggest increased daily walking, which is the largest component of daily physical 
activity (113, 114), is associated with decreased risk of cardiovascular events (122). 
Conversely, decreased walking has been shown to have a number of adverse health 
effects such as insulin resistance (109, 145) and obesity (114).  
Several recommendations have been given as to the number of steps individuals 
should accrue each day. Many cite a 10,000 step daily goal as a benchmark to improve 
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health, although this seems to be a rather arbitrary number that finds its origins nearly 60 
years ago in Japanese health clubs and pedometer promotions (189).  Further studies on 
this topic have focused on empirically-driven data to craft a daily step goal (119, 188). 
Tudor-Locke et al (195) and others (161) have found that, when translating the current 
PA guidelines into a standard daily step number, approximately 8,000 steps/day was 
consistent with obtaining the recommended 30 minutes/day of MVPA. 
While these studies are considered less extreme than studies of extended bed-rest 
and the like, they are still quite potent with relatively short interventions exerting sizable 
effects. Some authors have found reducing daily step numbers from >10,000 to <2,000 
steps/day in participants that VO2max decreased ~7% in just two weeks (108, 109). These 
data are underscored by the assertion made by Trappe et al (180) that the decline in 
cardiorespiratory fitness from ages 30 to 50 is due almost exclusively to the increase in 
physical inactivity. Further, as individuals age daily step counts decrease (190, 192, 215) 
even as daily walking makes up a greater portion of an individual’s total physical activity 
(182, 193).  
Furthermore, reduced ambulatory activity in durations shorter than a week have 
been shown to impair insulin sensitivity and elevated glucose responses to oral glucose 
tolerance tests (OGTT) (108, 109, 128, 145). By experimentally reducing daily step 
number for 1 week from ~10,500 to ~1,500 Olsen et al. (145) reported an increase of 
more than 52% in the area under the curve of plasma insulin during an (OGTT) with the 
potential to grow to nearly 80% greater, if the reductions were maintained for 2 more 
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weeks (145). This is due to a decrease in insulin sensitivity and increases in insulin and c-
peptide in response to an OGTT within 3 days of reduced ambulatory activity. Due to 
these changes, development of type 2 diabetes and metabolic syndrome become more 
prevalent in inactive individuals. In an analysis of 2,500 participants Vander Berg et al 
(197) found that for each additional hour of sitting or lying during the waking hours odds 
of developing type 2 diabetes increased 22% and 39% for development of metabolic 
syndrome. Interestingly these elevated odds were independent of participation in high-
intensity physical activity. Much less work has been done to directly investigate the effect 
of decreasing daily steps and PPL responses. However, a two-week reduction in steps has 
been associated with an increase of 27% in postprandial plasma triglyceride AUC (109, 
145). This indicates the effects may be similar to those on glucose metabolism.  
 
Exercise Resistance 
Recently an alarming phenomenon of ‘exercise resistance’ has been postulated by 
some in response to inactivity (1, 22, 38, 98). Relatively few studies have considered the 
effects of inactivity on metabolism in conjunction with acute and chronic exercise. This 
type of design is pertinent in a culture where individuals are able to achieve physical 
activity guidelines (i.e. a 30-minute brisk walk) and sit for 15 hours or more in the same 
day (64, 65). Epidemiologists have begun to recognize an alarming trend, identifying a 
subset of those classified as “physically active” are not fully realizing the protective 
effect of that activity (146). It seems that physical inactivity may cause the production of 
some unknown factors that impair normally healthy physiological stimuli, such as 
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exercise, from occurring or being realized. Or, alternatively, the adverse effects of a 
physically inactive lifestyle may be independent of the protective effects normally 
associated with exercise (36, 65, 146).  
A plausible explanation to this trend arose in 2016 when the term exercise 
resistance was coined in a recent paper from Kim et al. (98). In this study it was found 
that participants that sat for ~14 hours (<1700 steps) in their waking day did not respond, 
by attenuating the 6-hour PPL excursion, the morning after 1-hour of running at 63% of 
VO2max,. Yet, participants in a group that were not sitting to such an extent did improve 
PPL the morning after the acute exercise. Interestingly, this non-response was observed 
in groups of both eucaloric and hypercaloric energy balance (98). While this was a 
remarkable observation, the study was not designed to make definitive statements on 
‘exercise resistance’, as it did not include a non-exercise control group. In order to 
address this, a follow up study by Akins et al. (1) was conducted to test the existence of 
this phenomenon. Using a similar, randomized, cross-over design, this study employed 
inactivity to slightly lesser extent (~13.5h/day sitting and ~3600 steps/day) but provided 
an adequate control in which one of the two trials entailed prolonged sitting without 
exercise on the day before the HFTT. Following the 1h of exercise, the participants in 
this study showed no significant improvement in PPL, glucose or insulin excursions over 
6 hours compared to the non-exercise control group (1).  Thus, they appeared resistant to 
improving PPL as a results of the 1h of exercise. 
Cumulatively, these finding indicate that chronic inactivity abolishes the 
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beneficial effect of acute exercise on reducing PPL and bolstering fat oxidation. These 
data show that, in participants who experience prolonged periods of inactivity, an acute 
bout of exercise (e.g.; 1h of running) did not improve PPL. Due to this inactivity the body 
appears to be resistant to deriving one of the main acute health benefits of exercise; in 
this case attenuation of PPL.  
In yet another study, Duvivier et al. (38) asked participants to undergo one of 
three free living conditions. The participants either sat for 14 hours/day, sat for 13 
hours/day with 1-hour exercise bout interjected to replace an hour of sitting, and a 
condition with light physical activity that consisted of substituting 6 hours/day of  sitting, 
with 4 hours of walking, and 2 hours of idly standing. While both light PA and exercise 
increased energy expenditure above sitting, neither differed from each other in total 
energy expenditure even though the number of steps in the low-PA group was 5 to 6 
times higher (38). Interestingly, the 1-hour bout of exercise was not able to improve 
resting, fasting plasma triglycerides, cholesterol, or insulin concentration over sitting 
alone. Conversely, minimal-PA was able to improve resting, fasting plasma triglycerides 
and cholesterol over sitting and insulin concentration compared to the exercise group 
(38).  Although these results did not administer a HFTT and only reported no significant 
effect on fasting levels the morning after exercise, it agrees with but does not prove the 
concept of exercise resistance.   
Naturally, questions arise as to which is the likely culprit inducing this 
phenomenon of ‘exercise resistance’. Could it be there is something inherently harmful 
with the seated posture itself or, rather, is it due to a lack of contractile activity within the 
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muscle due to sitting? To answer this several studies have broken up prolonged periods of 
sitting with standing and found no discernable reductions of triglyceride iAUC (4, 74). 
Still, some doubted that the extent of standing employed in previous studies was 
sufficient to induce a significant difference. Crawford et al (31) had participants stand for 
12 hours, or more, on the day prior a HFTT. In this study, the standing intervention 
group, displayed plasma triglyceride and insulin iAUCs that were no different than a 
group who sat for more than 14 hours (31). In another study (211), participants completed 
40-sprint bouts of 4 sec on an inertial load ergometer. Participants either completed these 
bouts consecutively at the end of 8 hours of sitting, or five sprint bouts at the top of each 
hour over the 8 hours of sitting. While sitting time did not differ between groups, this 
study showed improved PPL on the following day in the individuals who spread the 
sprint bouts throughout the day but not in those who completed these bouts consecutively 
in the evening (211). The findings suggest that exercise resistance may arise if exercise is 
performed in the evening following a day of inactivity but can be avoided if the same 
level of activity is spread throughout the day. Interestingly, because daily inactivity and 
exercise were similar between groups, this study suggest the development of exercise 
resistance may be avoided with regular contraction spread throughout the waking hours. 
Regular contraction may be necessary to maintain healthy function and sensitivity to 
healthy stimuli. While the mechanisms are yet to be clearly elucidated, the observations 
of Lambernd et al (110) may provide insight as they observed that single muscle fibers 
treated with TNF- did not show impaired insulin sensitivity if they were also contracted.  
It is possible that physical inactivity causes the production of some factor(s) that impair 
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normally healthy physiological stimuli, such as exercise, from occurring or being 
realized.  This hypothesis agrees with the observation that people who exercise regularly, 
do not realize the decreased risk of cardiovascular disease or death if they also have 
lifestyles characterized by chronic inactivity, or that the exercise needs to be extreme in 
order to be protective (e.g.; 60-75 min vigorous each day)(39). 
Furthermore, available evidence suggests that this ‘exercise resistance’ may not 
be an exclusive phenomenon to just postprandial metabolism.  Breen et al. (22) found that 
reducing daily steps for two weeks, from ~6,000 steps to ~1400 steps, induced an 
‘anabolic resistance’. With the use of muscle biopsies, this study was able to show that 
the increase in myofibrillar protein synthesis, after consumption of high-grade protein, 
was attenuated by 26% in inactive participants compared to baseline, after 2 weeks of 
reducing daily step count. 
In light of these new and intriguing findings the interpretation of previous studies 
might be reconsidered. It is possible that inactivity impairs other healthy adaptations to 
normally effective stimuli.  While indirectly contested (131), this new evidence may 
provide additional insight by which the concept of non-response to acute and chronic 
exercise can, at least partly, be further elucidated. If these hypotheses can be generalized, 
it may provide an explanation for any study that found a non-response to a physiological 
stimulus in that it might be related to participants having a background of too much 
inactivity. It is possible this phenomenon may have been present in previous studies but 
has gone largely unrecognized due to a lack of evidence suggesting non-exercise activity 
may play a role in the hypothesized response. For example, Rogers et al. (159) found 7 
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days of aerobic exercise resulted in a significant improvement in glucose tolerance, 
measured as 3-hour area under the curve of plasma glucose excursion, in response to 
100g oral glucose tolerance test (OGTT) compared with a non-exercising control. This 
improvement occurred in the absence of cardiovascular adaptation and without changes 
in body mass or fat content. Thus these authors concluded the changes in glucose 
tolerance must be due to persistent effects of the last bout of exercise. These investigators 
again studied subjects after 6 months of sedentary, free-living, and found that OGTT after 
a single bout of exercise at the same intensity and duration as that was performed in the 
previous intervention failed to improve  plasma glucose or insulin responses following 
acute exercise (159). While this seemed counterintuitive to these authors at the time, 
recent evidence, including the emergence of exercise resistance, may shed light on a 
possible explanation to results that seemed perplexing by these authors own admission in 
1988.  It’s possible that the second group of subjects were too inactive to benefit from the 
acute bout of exercise. 
Possible Mechanisms Inducing Exercise Resistance 
 
Although these previous studies have demonstrated that inactivity, even with 
moderate exercise, has deleterious effects on triglyceride and glucose tolerance (1, 38, 98), 
none have directly investigated the mechanisms for exercise resistance. Therefore, current 
understanding requires speculation. Reduced activity of muscle LPL is perhaps the most 
likely explanation for the impaired triglyceride clearance (63). As previously described, 
LPL is upregulated post exercise inducing the insertion of additional extra binding sites on 
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the muscle’s capillary endothelium (76, 77, 91, 124). Because of the role of  LPL as the 
rate-limiting enzyme for removing chylomicrons and VLDL triglyceride from the 
circulation (201), hydrolysis of triglycerides from these carriers and subsequent uptake by 
the muscle would therefore be delayed (55). With the lack of difference in PPL with or 
without exercise found in the previous studies (1, 98), it seems inactivity can impair or 
completely abolish the exercise-induced upregulation of LPL. In an animal model, physical 
inactivity modeled by hind-limb unloading, significantly reduced the in vitro activity of 
muscle lipoprotein lipase, and decreased the amount of heparin-released LPL and may 
reduce its activity by up to 90% (15, 220). This difference in activity was seen without 
changes in LPL mRNA. This suggests the inhibition of LPL is post-transcriptional.  
One possible, post-transcriptional mechanistic explanation for this impairment 
could be thioredoxin-interacting protein (TXNIP). It was recently observed that 6-h of 
hind-limb immobilization in rats resulted in an increase in TXNIP protein expression and 
mRNA and a decrease in insulin-stimulated glucose uptake in the soleus muscle (94). It 
was speculated that this was possibly due to endocytosis and subsequent decrease in the 
amount of GLUT4 at the surface of the sarcolemma (94). It seems possible a similar 
process could affect plasma TG clearance by skeletal muscle via downregulation of LPL 
on capillary endothelium, either directly or indirectly through manipulation of GPIHBP1 
responsible for binding and tethering LPL to the luminal surface of the capillary  (12, 17). 
Whether the lack of contractile activity in humans that experience severe reductions in 
daily steps causes dramatic increases TXNIP remains to be determined. However, the 
previously mentioned increase in TXNIP with immobilization protocols can be 
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eliminated by activation of AMPK via AICAR administration (94). This adds additional 
credence to the hypothesis linking accumulation of TXNIP to lack of a precursor that 
senses energy turnover and exercise resistance. Interestingly, both TXNIP and LPL 
activity are sensitive to changes in contractile activity, even at low intensity such as those 
seen during leisurely walking (e.g. 30% VO2max) (15, 63).  Furthermore, AMPK 
activation has been shown to also upregulate LPL activity in skeletal muscle (116). 
Future studies are needed to test the hypothesis that AMPK activation prevents TXNIP 
elevation and allows a healthy increase in GLUT4 and LPL to augment the uptake of 




While we know that exercise is beneficial for health and wellness, we are just 
learning that inactivity is more than the lack of exercise and it seems to be having a 
separate impact on health independent of exercise. This is especially true in light of 
emerging evidence suggesting that this exercise may not reduce the  risk of developing 
chronic disease and premature mortality against a background of inactivity.  
Future research should expand on the newfound ‘exercise resistance’ hypothesis 
and the nature of this phenomenon, determining if it extends beyond the measures of 
PPL. It would be increasingly useful for the medical practitioner, exercise scientist, and 
public health professionals to understand this and how to counteract it. If inactivity 
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progressively encroaches on adaptations to aerobic exercise in a ‘dose-response’ fashion 
or occurs at some threshold, further characterizing this would be invaluable to identify 
what minimum level of activity is necessary to fully realize the full and proper responses 
to acute and chronic exercise. 
 Furthermore, while current research is beginning to expound on the inability of 
exercise to improve indices of health, much of the work has focused solely on acute bouts 
of exercise. It is vital that data be provided to expand on ‘exercise resistance’ and its 
presence or absence in response to an accumulated training stimulus. Investigations into 
postprandial metabolism have shown great merit and have been shown to be sensitive to 
changes induced by inactivity. However, it is also important to investigate if these 
adverse responses, including ‘exercise resistance’, extend to other cardiometabolic 
responses to exercise training beyond PPL. In doing so, the data provided would provide 
substantial evidence which could aid in crafting additional and more tangible guidelines 
for health and wellness. The current guidelines are currently limited to generalities such 
as “move more, sit less” and “avoid inactivity”. This seems to be a result of suffering 
from a lack of quantitative evidence on the effects of inactivity. It is prudent to avoid 
development of prescriptive standards without sufficient data to buttress them. 
Nevertheless, this only underscores the need for more systematic examination of varying 
degrees of inactivity and their effect on markers of health. While these are laudable in 
their intent, the lack of definitive, quantitative conclusions on inactivity relegate these 
guidelines to subjective interpretation and can cause disparate effects from group to 
group, and individual to individual.  
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 Lastly, whether it be accumulation of TXNIP or some other co-factor within the 
muscle, it is important for future research to elucidate the mechanism by which ‘exercise 
resistance’ develops and, again, if it is limited mainly to PPL. A mechanistic 
understanding of this phenomenon would be of great benefit to practitioners and scientist 




APPENDIX A: METHODOLOGICAL TECHNIQUES 
 
Oxygen Consumption 
During exercise the participants breathed through a two-way non-rebreathing 
valve (Hans Rudolph, Kansas City, MO). Ventilation was measured via an inspiratory 
pneumotachometer attached to the two-way valve (Hans Rudolph, Kansas City, MO). 
Expired gas samples were taken from a mixing chamber which was directly connected 
via capillary tubing to oxygen and carbon dioxide analyzers (Applied Electrochemistry, 
Models S-3A/I and CD-3A, respectively). MOXUS metabolic software (Applied 
Electrochemistry) was then used to continuously analyze VO2 and VCO2 
 
Near-Infrared Spectroscopy 
Near-infrared spectroscopy (NIRS) (OxiplexTS, ISS Oximeter Model 95205, 
Champaign, IL) was used to measure deoxygenated hemoglobin [HHb] during exercise in 
a thigh muscle (i.e.; vastus lateralis). NIRS analyzes the chromophores of O2Hb and 
HHb, which have different optical properties of absorbing near-infrared (wave length: 
690 nm, 830 nm). This enables NIRS to measure the absolute concentrations of O2Hb 
and HHb in real-time and noninvasively (21, 57, 136). 
 Before every test, the NIRS was calibrated after about 30 minutes of warm-up. 
Figure 12 shows the description of the probe designed for skeletal muscle measurements 
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and this probe was used for this study. The schematic of the near-infrared light 
penetrating 2.0 cm, 2.5 cm, 3.0 cm, and 3.5 cm in depth from skin. The acquisition 
frequency of 2 Hz was used for this study. NIRS data was continuously monitored and 
averaged between minutes 9 and 10 of submaximal exercise tests for data analysis. 
 
 
Figure 12. Diagram of OxiplexTS probe for measuring deoxygenated hemoglobin in 
skeletal muscle during submaximal exercise 
 
 
Blood Lactate Measurements 
 
Blood lactate concentration was determine using the following procedures and enzymatic 
reactions:  
 




1. Acupette capillary tubes    Qty: 2 per blood sample? 
2. Eppendorf 1.5ml tube                                       Qty:((x+3)*2) 
3. Polyproylene 12 x 75 mm test tube                Qty: (2 per blood sample) 
  
Solutions and Reagents 
1.  NAD   Sigma N-7004 
2. LDH   Sigma L-3916 
3. Hydrazine   Sigma H-9507 
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4. Glycine   Fisher G-46 
5. Lactate Std   Sigma 826-10 
6. Perchloric Acid Fisher A-229 70% 
 
PCA: to get 8%, take 57.14ml of 70% stock, bring to 500ml with dH20 
 
Glycine-Hydrazine Buffer for 1000ml 
0.33M glycine    25.02g 
0.27M hydrazine   23.98mL 
Mix and bring up to 1000mL with dH20, pH to 9.2 
 
Part 2: Sample Preparation 
 
Step 1:    Prepare Reagent Cocktail 
1. Prepare reagent cocktail for each sample or tube 
a. 1ml of glycine-hydrazine buffer 
b. 0.83mg of NAD 
c. 5uL of LDH, if using 1000ul/ml stock, need 5ul 
2. If you have X blood samples: 
 . ((x+3)*2 +1)  of the above cocktail recipe 
a. Need the samples, one blank, two standards, all in duplicate, plus one extra so you have 
enough buffer for all of your samples 
 
Step 2: Blood deproteinization 
1. Protective gloves, glasses, and lab coat should be used when handling blood 
2. Exactly 0.5mL of whole blood should be immediately mixed with 1.5 mL 8% PCA in 
Eppendorf tube 
3. Vortex the tube to fully deproteinize the sample 
4. Centrifuge at 4degreesC for at least 15min t 3000RPM 
5. Transfer the clear supernatant to an appropriately labeled tube 
a. Lactate is stable in supernatant for at least one week at 2-6degrees C, longer if frozen 
Step 3: Supernatant/ Reagent Mixture 
1. Add 1ml of reagent cocktail (see part 2, step 1 above) 
2. Add 50uL of 8% PCA to the Eppendorf 1.5mL tubes for the blank 
3. Add 50uL of two lactic acid standards to std1 and std2 Eppendorf 1.5ml tube. 
4. Add 50uL of sample supernatant to sample 1 to sample N Eppendorf 1.5mL tubes. 
5. Vortex each Eppendorf tube 
6. Incubate tubes at 37degrees C for 45 min in shaking water bath at 60RPM 
 
Part 3: Sample Analysis 
 
Step 1: Spectrophotometer and Calculations 
1. Warm the spectrophotometer for 30 min, read the sample at 340nM 
a. Instrument: Spectrophotometer Beckmann DU-600 
b. Method: A:\LAT 
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c. Read average time: 0.5s 
d. Fixed wavelength: 340nM 
e. Factor 10.13 
2. Calculations  
Lactate standard 40mg/100ml, 400mg/L, or 4.44mM (Sigma 826-10, now Trinity Biotech 82610) 
i.Low 10mg/100mL   (1.11mM) 
ii.High 20mg/100mL  (2.22mM) 
a. Abs/E.C. = Abs/6.22 
b. 1.05/0.05 = cuvette dilution (0.05mL blood in 1mL reagent cocktail) 
c. Standard concentration = Abs/6.22 x cuvette dilution = Abs x 3.38 
d. 3/1 = blood dilution (0.5mL blood in 1.5mL of 8% PCA) 
e. Sample concentration = (Abs/6.22) x 1.05/0.05 x 3/1 = Abs x 10.13mM 
f. [La] = abs x 10.13mM 
 
Plasma Glucose Measurement  
Plasma glucose we measured via spectrophotometry using commercially available 
kits (Pointe Scientific, Inc. Canton, USA). The plasma samples were removed from freezer 
(-80°C) and thawed. 5 μL of plasma sample is added to 500 μL of glucose hexokinase 
reagent and then incubated at room temperature for 3 minutes, following gentle mixing via 
a benchtop votex machine. Glucose is phosphorylated with ATP to produce glucose 6-
phosphate (G-6-P) in the reaction catalyzed by hexokinase (HK). The glucose 6-phosphate 
is then oxidized via reduction of NAD to NADH in the reaction catalyzed by glucose 6-
phosphate dehydrogenase (G6PDH). The absorbance of NADH formed was measured at 
340 nm using a via spectrophotometry (Cary Eclipse Florescence Spectrophotometer, 
Agilent Technologies, Santa Clara, California). The concentration of NADH is directly 
proportional to the concentration (mg•dL-1) of glucose in the sample.  
Plasma Triglyceride Measurement 
Plasma triglyceride was measured via spectrophotometry using a commercially 
available kit (Pointe Scientific, Inc., Canton, USA). Samples were removed from freezer 
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(-80°C) and thawed. 3.5 μL of plasma is then pipetted off and added to 350 μL of pre-
warmed (37°C) triglyceride reagent. These samples are and incubated for 30 minutes on 
an oscillating tray in a warm (37°C) oven. The reagent hydrolyzes triglycerides in the 
sample via lipase and produces glycerol and free fatty acids. Glycerol is then 
phosphorylated by ATP to glycerol 1- phosphate and ADP through a reaction catalyzed 
by glycerol kinase (GK). The glycerol 1-phosphate is then oxidized by glycerol 
phosphate oxidase (GPO) to yield hydrogen peroxide. The condensation of hydrogen 
peroxide with 4-chlorophenol and 4- aminophenazone (4-AA) in the presence of 
peroxidase (POD) produces a red colored quinonimine dye. The intensity of the colored 
complex formed is directly proportional to the triglycerides concentration of the sample. 
The plate is read at 500 nm using a microplate reader (Tecan Infinite 200 PRO, Tecan 
Group Ltd., Männedorf, Switzerland). 
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APPENDIX B: RESEARCH CONSENT FORMS 
Consent for Participation in Research 
Title:  
The Effect of Prolonged Sitting on Metabolic and Cardiovascular Responses to Short 
Term Exercise Training 
 
Introduction 
The purpose of this form is to provide you information that may affect your decision as to 
whether or not to participate in this research study.  The person performing the research 
will answer any of your questions.  Read the information below and ask any questions 
you might have before deciding whether or not to take part. If you decide to be involved 
in this study, this form will be used to record your consent. 
 
Purpose of the Study 
The purpose of this study is to investigate the effect of daily sitting time on plasma 
triglycerides, artery function and other training adaptations resulting from 1.5 weeks of 
intense cycle training. 
 
What will you be asked to do? 
Before you can be admitted to the study, you will be given brief preliminary tests. This 
will include filling out a brief Health Research Questionnaire, and taking measurements 
of your height and weight. Only if you are apparently healthy and at low risk for 
cardiovascular disease will you be invited to participate in this study. Prior to your 
enrollment in the study, your peak oxygen uptake (VO2peak) will be determined while 
exercising on a cycle ergometer (lab exercise bike) and also your heart rate during 
submaximal cycling will be determined.  
Participation will span seventeen days, with periodic visits to the Human Performance 
Laboratory (HPL).  You will randomly assigned to one of two groups: 
Low Sitting Group: Metabolic and cardiovascular responses to exercise program and low 
sitting lifestyle (sitting <5h/d, >15,000 steps/d) outside of exercise. 
High Sitting Group: Metabolic and cardiovascular responses to exercise program and 
high sitting lifestyle (sitting >11h/d, <2,500 steps/d) outside of exercise. 
 
Step-by-Step Protocol: 
Pre-Intervention Phase (Week 1) 
Day 1: High Fat Tolerance Test  (HFTT) and Flow Mediated Dilation 
1. Arrival at the Human Performance Laboratory (HPL), informed consent, health history 
questionnaires, body mass and height. 
2. Flow mediated dilation measurement. 
3. Catheter insertion and fasting blood collection. 
4. High fat shake consumption 
5. Postprandial blood sampling hourly for 6 h (6 additional samples). 
6. Expired gas collection for 20 minutes at baseline and 1, 3, 5 h after high fat shake intake. 
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7. Post HFTT flow mediated dilation measurement (FMD) 
 
■ Total time: 430 minutes 
Day 2: VO2peak test 
1. Arrival at HPL, body mass measurement. 
2. Warm up for 5 minutes. 
3. Perform peak oxygen consumption test; (VO2peak test, 8-12 min.)  
4. Installation of the activity monitor.  
■ Total time: 30 minutes 
Day 3: Submaximal Exercise test 
1. Arrival at HPL, body mass measurement. 
2. Catheter insertion and baseline blood collection. 
3. Warm up for 5 minutes at 50% VO2peak. 
4. Perform continuous 15-minute submaximal exercise at 80% VO2peak and collect blood at 15 
min. 
5. 5 min post exercise blood collections. 
 
Day 4 and 5: Low energy expenditure 
1. No Testing will be done on these days but subjects will need to be cognizant of sitting 
time and step count to keep it low 
Day 6: Initial training bout 
1. Arrival at HPL, body mass measurement. 
2. 5-minute warm up. 
3. 20-minute cycling bout at 80% VO2peak. 
4. 10-minute rest interval. 
5. Two 5-minute interval exercise bouts at 95% VO2peak, with 5 min rest 
■ Total time: 60 minutes 
Day 7: High Fat Tolerance Test and Flow Mediated Dilation  
(To examine the acute effects of the single bout of exercise performed the day before). 
1. Arrival at HPL, body mass and height measurement. 
2. Flow mediated dilation measurement. 
3. Catheter insertion and fasting blood collection. 
4. High fat shake consumption. 
5. Postprandial blood sampling hourly for 6 h (6 additional samples) 
6. Removal of activity monitor. 
7. Expired gas collection for 20 minutes at baseline and 1, 3, 5 h after high fat shake 
intake. 
8. Post HFTT flow mediated dilation measurement. 
9. Reattachment of activity monitor. 
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■ Total time: 420 minutes 
Training Phase (Week 2) 
Day 1, 3 , 5 & 7: Training Days 
1. Arrival at HPL, body mass measurement. 
2. 5-minute warm up. 
3. 20-minute cycling bout at 80% VO2peak. 
4. 10-minute rest interval. 
5. Two 5-minute interval exercise bouts at 95% VO2peak. 
■ Total time: 240 minutes (60 min each of 4 days) 
Post-Intervention Phase (Week 3) 
Day 1: High Fat Tolerance Test and Flow Mediated Dilation 
1. Arrival at HPL, body mass  
2. Flow mediated dilation measurement. 
3. Catheter insertion and fasting blood collection. 
4. High fat shake consumption. 
5. Postprandial blood sampling hourly for 6 h (6 additional samples). 
6. Removal of activity monitor. 
7. Expired gas collection for 20 minutes at baseline and 1, 3, 5 h after high fat shake intake. 
8. Post HFTT flow mediated dilation measurement. 
 
■ Total time: 420 minutes 
Day 2: Post-training submaximal exercise test 
1. Arrival at HPL, body mass measurement. 
2. Catheter insertion and baseline blood collection. 
3. Warm up for 5 minutes. 
4. Perform continuous 15-minute submaximal exercise at 80% VO2peak (of pretaining VO2peak) 
5. Post exercise blood collections. 
■ Total time: 40 minutes 
Day 3: Post-training VO2peak test. 
1. Arrival at the HPL, body mass.. 
2. Warm up for 5 minutes. 
3. Perform continuous peak oxygen consumption test; (VO2peak test, 8-12 min.)  
 
■ Total time: 40 minutes 
Total time per subject for both trials is approximately 28h ( 1,680 minutes) over 17 
days.  
 
What are the risks involved in this study? 
None of the above procedures are expected to be unduly painful or unsafe in healthy 
individuals. Maximal and submaximal cycling tests as well as the 30-minute training 
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sessions will all be performed in comfortable environmental conditions (e.g. 20 - 25 º C 
and relative humidity of ~ 50%). During VO2peak testing, the last 2-4 minutes of the test 
may cause a feeling of fatigue and heavy breathing similar to performing ‘high intensity 
interval training’. This feeling of fatigue generally subsides soon after completion (e.g. 
within 2-10 minutes). However, with all aerobic exercise, there is a risk of cardiovascular 
events. The risk of any sort of cardiovascular complication in apparently healthy (no 
documented CV disease) individuals is very low with no complications in 380,000 tests. 
Furthermore, in over 35 years involving several thousand exercise sessions, no subject in 
the Human Performance Lab has experienced any cardiac event. During each trial, an 
AED will be present and a CPR certified test administrator will be present. There is a 
small risk of muscular injury or muscular soreness within 24- to 48-hours post-session. 
To reduce these risks, a brief warm-up period will be performed. 
Blood samples will be drawn during each HFTT and submaximal exercise visit via a 
venous catheter in the forearm or antecubital vein. A certified phlebotomist will insert all 
catheters. Minor discomfort may occur during the insertion of the catheter. The 
discomfort associated with the insertion of the catheter is similar to a venipuncture. Risks 
associated with placement of the catheter include bleeding, pain, swelling, bruising, 
infection, and thrombophlebitis. Each blood draw will be approximately 6 mL of blood or 
the equivalent of 162 mL for the entire experiment. This amount of blood is 
approximately 11 tablespoons, and less than 4% of total blood volume. After analysis, if 
subjects are found to have abnormally high fasting or post-prandial triglyceride levels, 
they will be alerted of this and advised to follow-up with their primary care physician.  
The activity monitor will be placed on your leg the day before study participation 
commences. Participants may experience a low level annoyance.  The activity monitor 
will be detached for 30-60 min to load data to a computer.  Subjects will carry a 
pedometer attached to their waist for a week before the initiation of the first trial for the 
estimation of an average daily steps and throughout the trials. It will not give participants 
any discomfort.  
During the tests, participants may stop performing the task at any time and for any reason 
if he or she feels the need to do so. If participants wish to discuss the information above 
or any other risks participants may experience, participants may ask questions now or call 
the Principal Investigators. 
 
What are the possible benefits of this study? 
You will receive no direct benefit from participating in this study; however, each subject 
completing the study will be provided with a graphic and verbal description and 
explanation on their peak aerobic capacity, heart rate, blood pressure and metabolic 
responses both in fasted and non-fasting states in response to different prior physical 
activity/inactivity status.  
 
Do you have to participate? 
No, your participation is voluntary. You may decide not to participate at all or, if you 
start the study, you may withdraw at any time.  Withdrawal or refusing to participate will 
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not affect your relationship with The University of Texas at Austin (University) in 
anyway.  
If you would like to participate please fully read, sign, and return this form to the 
principal investigator of this study (Heath Burton).  You will receive a copy of this form 
for your personal records. 
 
Will there be any compensation? 
You will not receive any type of payment participating in this study.  
  
What if you are injured because of the study?   
1. The University has no program or plan to provide treatment for research related 
injury or payment in the event of a medical problem.  In the event of a research 
related injury, please contact the principal investigator. 
2. The University has no program or plan for continuing medical care and/or 
hospitalization for research-related injuries or for financial compensation. 
3. If injuries occur as a result of study activity, eligible University students may be 
treated at the usual level of care with the usual cost for services at the Student 
Health Center, but the University has no program or plans to provide payment in 
the event of a medical problem. 
 
How will your privacy and confidentiality be protected if you participate in this 
research study? 
Each subject will be assigned a unique Subject ID code.  This informed consent form and 
the Health History Questionnaire are the only places where any personal identifying 
information will be recorded.  These forms will be stored in a locked file cabinet.  In all 
other cases, your data will only be identifiable by your unique code.  Only the director of 
the laboratory (Dr. Coyle) will have access to a master list that will link your identity to 
your code. 
Because you will be participating in this study and may do so along with other subjects in a 
small group, we will ask that you do not disclose names of participants in your group or 
any information that was discussed with other group members outside of the experimental 
session.  
If it becomes necessary for the Institutional Review Board to review the study records, 
information that can be linked to you will be protected to the extent permitted by law. 
Your research records will not be released without your consent unless required by law or 
a court order. The data resulting from your participation may be made available to other 
researchers in the future for research purposes not detailed within this consent form. In 
these cases, the data will contain no identifying information that could associate it with 
you, or with your participation in any study. 
If you choose to participate in this study, you may be photographed or video recorded.  
Any photographs or video recordings will be stored securely and only the research team 
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will have access to the recordings.  Recordings will be kept for 3 years after the research 
experiment has been completed and then erased.   
 
Whom to contact with questions about the study?   
Prior, during or after your participation you can contact the researcher Heath Burton at 
(864)-940-4103 or send an email to heath.burton@utexas.edu for any questions or if you 
feel that you have been harmed.   
This study has been reviewed and approved by The University Institutional Review 
Board and the study number is 2017-07-0074 
 
 
Whom to contact with questions concerning your rights as a research participant? 
For questions about your rights or any dissatisfaction with any part of this study, you can 
contact, anonymously if you wish, the Institutional Review Board by phone at (512) 471-
8871 or email at orsc@uts.cc.utexas.edu.  
 
Participation 
 If you agree to participate please sign and return this form to a member of the 
research team. 
 
Signature   
You have been informed about this study’s purpose, procedures, possible benefits and 
risks, and you have received a copy of this form. You have been given the opportunity 
to ask questions before you sign, and you have been told that you can ask other 
questions at any time. You voluntarily agree to participate in this study.  By signing this 
form, you are not waiving any of your legal rights. 
Photography and video recording of your sessions is optional. However, if 
participants agree to be photographed or video recorded their images may also 
be used for professional and educational presentations not related to this 
research study. 
______ I agree to be photographed and video recorded. 
______ I do not want to be photographed and video recorded. 
_________________________________ 
Printed Name  
_________________________________    _________________ 
Signature Date 
As a representative of this study, I have explained the purpose, procedures, benefits, and 
the risks involved in this research study. 
_________________________________      
Print Name of Person obtaining consent      
 
_________________________________    _________________  
Signature of Person Obtaining Consent     Date 
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Consent for Participation in Research 
Title:  
Dose Response of Physical Inactivity on Plasma Triglyceride Elevation After a Meal.  
 
Introduction 
The purpose of this form is to provide you information that may affect your decision as to 
whether or not to participate in this research study.  The person performing the research 
will answer any of your questions.  Read the information below and ask any questions 
you might have before deciding whether or not to take part. If you decide to be involved 
in this study, this form will be used to record your consent. 
 
Purpose of the Study 
The purpose of this study is to investigate the effect of two days of reduced daily 
stepping, and moderate exercise on plasma triglyceride elevation after a meal. 
 
What will you be asked to do? 
Before you can be admitted to the study, you will be given brief preliminary tests. This 
will include filling out a brief Health Research Questionnaire, and taking measurements 
of your height and weight. Only if you are apparently healthy and at low risk for 
cardiovascular disease will you be invited to participate in this study. Prior to your 
enrollment in the study, your maximal oxygen uptake (VO2max) will be determined while 
running on a treadmill and also your heart rate during submaximal running will be 
determined.  
Each trial will require five days, with periodic visits to the HPL: 
Trial 1: Plasma triglyceride responses with two days of 2,500 steps per day and a single 
one-hour bout of exercise on the night of the fourth day. 
Trial 2: Plasma triglyceride responses with two days of 5,000 steps per day and a single 
one-hour bout of exercise on the night of the fourth day. 
Trial 3: Plasma triglyceride responses with two days of 7,500 steps per day and a single 
one-hour bout of exercise on the night of the fourth day. 
The order of protocols will be randomized.  
 
Step-by-Step Protocol: 
Week prior to the initiation: Health history questionnaires, familiarization, VO2max test. 
5. Arrival at the Human Performance Laboratory (HPL), informed consent, health history 
questionnaires, body mass and height. 
6. Installation of the activity monitor. 
7. Perform resting gas measurement.  
8. Warm up for 5 minutes on a treadmill. 
9. Perform submaximal exercise test with four treadmill speeds lasting five minutes each.  The 
intensity will approximate 40, 60, 70 and 80% of age predicted maximal heart rate. 
10. Recover for ~ 15-20 minutes (re-hydrate to pre-exercise bodyweight) 
11. Perform continuous maximal oxygen consumption test; (VO2max test, 8-12 min.)  
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■ Total time: 150 minutes 
Trial sessions 
Control Phase: Control Day 1 and 2 (C1 and C2) 
 
Day prior to Control day 1: Activity monitor installation 
1. Arrival at the laboratory any time before 17:00 h. 
2. Installation of activity monitor 
 
- Total time: 30 minutes 
 
■ Total time spent during Control Phase: 30 minutes 
Intervention Phase: D1  
 
Day 1: Reduced daily steps 
1. Sitting in preferred place to accommodate step reductions (not necessarily in HPL). 
 
 
Day 2: Reduced daily steps & 1-hr treadmill running  
1. Sitting in preferred place to accommodate step reductions (not necessarily in HPL). 
2. Arrival at HPL at 16:50 h. 
3. Exercise at 65%VO2max for one hour at around 17:00 h 
4. Dinner provided in the laboratory. 
 
- Total time: 120 min   
 
Day 3: High fat tolerance test and resting fat oxidation 
8. Arrival at HPL, body weight, 8:00 h. 
9. Catheter insertion and fasting blood collection. 
10. High fat shake intake 
11. Postprandial blood sampling hourly for 6 h (6 additional samples) 
12. Expired gas collection for 10 minutes at 2, 4, 6 h after high fat shake intake 
13. Detachment of the activity monitor  
 
- Total time: 420 minutes 
 
■ Total time spent during Intervention Phase:  
- All Trials: 600-700 minutes 
Total time per subject for all trials is approximately 1900 minutes 
 
What are the risks involved in this study? 
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None of the above procedures are expected to be unduly painful or unsafe in healthy 
individuals. The maximal oxygen uptake (VO2max), submaximal tests, and 1 hour of 
moderate exercise at 65% VO2max will be performed at 20 - 25 º C and relative 
humidity of ~ 50%. During VO2max test, only the final 2 to 4 minutes of the test is at 
or near maximal levels of exertion and thus accompanied by a sensation of leg fatigue 
and heavy breathing. This moderate feeling of fatigue will subside soon after 
completion (i.e.; 2-10 min).  There is a very small risk that participants could 
experience a muscular injury, such as muscle strain. It is also possible that muscle 
soreness may develop 24 to 48 hours after any given testing session. To help reduce 
these risks, a warm up session will be mandatory prior to performing these tests.  
Blood samples will be drawn during each HFTT via venous catheter in an antecubital 
vein. A certified phlebotomist will insert the catheters. Minor discomfort may occur 
during the insertion of the catheter. The discomfort associated with the insertion of 
the catheter is similar to a venipuncture. Risks associated with placement of the 
catheter include bleeding, pain, swelling, bruising, infection, and thrombophlebitis. 
Approximately 42 ml of blood will be drawn per trial. Over the course of the entire 
study approximately 126 ml of blood will be drawn. This sample volume is 
approximately 2.3 % of the individual’s total blood volume. If participants are found 
to have abnormally high triglyceride levels, they will be alerted of this and advised to 
follow-up with their primary care physician. 
The risk of any sort of cardiovascular complication in apparently healthy (no 
documented CV disease) individuals is very low, with no complications in numerous 
tests. Furthermore, in over 36 years involving more than 50,000 exercise sessions, no 
subject in the Human Performance Lab has experienced any cardiac event. The 
laboratory is currently equipped with AED. A CPR certified member of the research 
team will be present during all testing visits in the unlikely event of an adverse 
reaction. 
During the tests, participants may stop performing the task at any time and for any reason if 
he or she feels the need to do so. If participants wish to discuss the information above or any 




What are the possible benefits of this study? 
You will receive no direct benefit from participating in this study. However, each subject 
completing the study will be provided with a graphic and verbal description and 
explanation on their maximal aerobic capacity, heart rate, blood pressure and metabolic 
responses both in fasted and non-fasting states in response to different prior physical 
activity/inactivity status.  
 
Do you have to participate? 
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No, your participation is voluntary. You may decide not to participate at all or, if you 
start the study, you may withdraw at any time.  Withdrawal or refusing to participate will 
not affect your relationship with The University of Texas at Austin (University) in 
anyway.  
If you would like to participate please fully read, sign, and return this form to the 
principal investigator of this study (Heath Burton).  You will receive a copy of this form 
for your personal records. 
 
Will there be any compensation? 
You will not receive any type of payment participating in this study.  
 What if you are injured because of the study?   
4. The University has no program or plan to provide treatment for research related 
injury or payment in the event of a medical problem.  In the event of a research 
related injury, please contact the principal investigator. 
 
5. The University has no program or plan for continuing medical care and/or 
hospitalization for research-related injuries or for financial compensation. 
 
6. If injuries occur as a result of study activity, eligible University students may be 
treated at the usual level of care with the usual cost for services at the Student 
Health Center, but the University has no program or plans to provide payment in 
the event of a medical problem. 
 
How will your privacy and confidentiality be protected if you participate in this 
research study? 
Each subject will be assigned a unique Subject ID code.  This informed consent form and 
the Health History Questionnaire are the only places where any personal identifying 
information will be recorded.  These forms will be stored in a locked file cabinet.  In all 
other cases, your data will only be identifiable by your unique code.  Only the director of 
the laboratory (Dr. Coyle) will have access to a master list that will link your identity to 
your code. 
Because you will be participating in this study and may do so along with other subjects in a 
small group, we will ask that you do not disclose names of participants in your group or 
any information that was discussed with other group members outside of the experimental 
session.  
If it becomes necessary for the Institutional Review Board to review the study records, 
information that can be linked to you will be protected to the extent permitted by law. 
Your research records will not be released without your consent unless required by law or 
a court order. The data resulting from your participation may be made available to other 
researchers in the future for research purposes not detailed within this consent form. In 
these cases, the data will contain no identifying information that could associate it with 
you, or with your participation in any study. 
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If you choose to participate in this study, you may be photographed or video recorded.  
Any photographs or video recordings will be stored securely and only the research team 
will have access to the recordings.  Recordings will be kept for 3 years after the research 
experiment has been completed and then erased.   
 
Whom to contact with questions about the study?   
Prior, during or after your participation you can contact the researcher Heath Burton at 
(864)-940-4103 or send an email to heath.burton@utexas.edu for any questions or if you 
feel that you have been harmed.   
This study has been reviewed and approved by The University Institutional Review 
Board and the study number is: 
 2018-08-0031  
 
Whom to contact with questions concerning your rights as a research participant? 
For questions about your rights or any dissatisfaction with any part of this study, you can 
contact, anonymously if you wish, the Institutional Review Board by phone at (512) 471-
8871 or email at orsc@uts.cc.utexas.edu.  
 
Participation 
 If you agree to participate please sign and return this form to a member of the 
research team. 
 
Signature   
You have been informed about this study’s purpose, procedures, possible benefits and 
risks, and you have received a copy of this form. You have been given the opportunity 
to ask questions before you sign, and you have been told that you can ask other 
questions at any time. You voluntarily agree to participate in this study.  By signing this 
form, you are not waiving any of your legal rights. 
Photography and video recording of your sessions is optional. However, if 
participants agree to be photographed or video recorded their images may also 
be used for professional and educational presentations not related to this 
research study. Therefore, these may be kept indefinitely.   
______ I agree to be photographed and video recorded. 
______ I do not want to be photographed and video recorded. 
_________________________________ 
Printed Name  
_________________________________    _________________ 
Signature Date 
As a representative of this study, I have explained the purpose, procedures, benefits, and 
the risks involved in this research study. 
_________________________________      
Print Name of Person obtaining consent      
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_________________________________    _________________  





APPENDIX C: HEALTH HISTORY QUESTIONNAIRE 
HEALTH HISTORY QUESTIONNAIRE 







Date of Birth (mm/dd/yy) ____________________________  
Age: ________________________ 
MALE _____ FEMALE ____ 













HEALTH HISTORY QUESTIONNAIRE 
HUMAN PERFORMANCE LABORATORY – THE UNIVERSITY OF TEXAS 
Subject ID:____________ 
 
GENERAL HEALTH QUESTIONS 
1. Are you taking any of the following medications on a regular basis? Y / N 
(Psychotropics, Antihistamines, Asthma Meds, Aldomet, Clonidine,Anti-Depressants, 
Anti-Anxiety Meds) 
2. Any over-the-counter meds? Y / N 
If yes, explain: 
3. Do you have any disability or impairment that affects physical performance? Y / N 
4. Have you ever had any broken bones, surgery or injury to your lower extremities? Y/N 
If yes, explain: 
5. Have you had any significant medical problems within the last 10 years? Y / N 
If yes, explain: 
6. Do you have any drug and/or alcohol dependence? Y / N 
If yes, explain: 
7. Do you have any heart problems or coronary artery disease? Y / N 
If yes, explain. 
8. Do you have hypertension (high blood pressure)? Y / N 
If yes, explain. 
9. Do you have any lung or respiratory problems? Y / N 
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If yes, explain. 
10. Do you, or have you previously had a history of blood clotting issues Y / N 
If yes, explain. 
11. Have you been diagnosed with diabetes? Y / N 
12. Are you currently pregnant? Y / N 
13. Do you smoke? Y / N 
If yes, pattern. 
14. Do you use alcohol? Y / N 
If yes, pattern. 
15. Do you use caffeine (cola, coffee, etc…)? Y / N 
If yes, pattern. 
16. Do you have any allergies that require medication? Y / N 
If yes, explain. 
17. Do you experience difficulty swallowing medications or vitamins? Y / N 
If yes, explain. 
18. Do you take any dietary supplements to increase your exercise performance? Y / N 
If yes, what supplements so you normally take? 
19. Have you been diagnosed with an obstructive disease of the gastrointestinal tract 
including but not limited to esophageal stricture, diverticulous, inflammatory bowel 
disease (IBD), peptic ulcer disease, Crohn’s disease,ulcerative colitis, and previous 
gastro-esophageal surgery. Y / N 
HAVE YOU EVER HAD ANY SIGNIFICANT SYMPTOMS ASSOCIATED 
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WITH EXERCISE? 
1. Easy fatigability or prolonged fatigue after exercise? Y / N 
If yes, explain. 
2. Persistent chest pain during and/or after exercise? Y / N 
If yes, explain. 
3. Fainting or loss of consciousness during exercise? Y / N 
If yes, explain. 
4. Palpitations (rapid, irregular, or skipped heartbeats) during exercise? Y / N 
5. Have you ever been told to give up sports because of a health problem? Y / N 
PHYSICAL TRAINING HISTORY 
How many years have you been training? 
_______________________________________________________________________ 
What type of physical training do you participate in? 
_______________________________________________________________________ 




















PLEASE GENERALLY DESCRIBE YOUR TRAINING PROGRAM DURING 
THE LAST 6 MONTHS 


























































































































































































































































































































































































































































































































































High Step Low Step 
AUCT AUCI AUCT AUCI 
Baseline 886.8  79.6 322.9  67.2 929.4  73.3 295.9  40.3 
Acute Exercise 760.9  73.7† 221.7 49.7* 967.5  98.6 291.6  66.5 
Post Training 762.2  65.5† 236.7 61.4* 890.4  64.9 257.8  27.0 
Note: Data are presented as MSE. (*) Significantly different from Baseline, p<0.05. (†) significantly different from baseline, 
p<0.01 
Table 11. Total and incremental areas under the curve of plasma triglyceride 
concentrations during HFTTs at Baseline, following a single bout of exercise (Acute), 
and following 5 training bouts over the 9-days of training (Post Training). (*) 
Significantly different from Baseline, p<0.05. (†) significantly different from Baseline, 
p<0.01. All Data are reported as Mean  SE. 
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Table 12. Total and incremental areas under the curve of plasma glucose concentrations 
during HFTTs at Baseline, following a single bout of exercise (Acute), and following 5 




High Step Low Step 
AUCT AUCI AUCT AUCI 
Baseline 726.335.1 146.0 38.6 704.326.2 145.031.2 
Acute Exercise 701.719.3 148.628.0 758.858.6 180.747.5 
Post Training 693.820.9 142.821.6 741.348.4 160.235.9 





Baseline H1 H2 H3 H4 H5 H6 
Triglycerides (mg/dL)       
Baseline 94.0  3.5 144.9  6.2 163.3  21.4 174.4  23.2 152.4  14.6 138.8  9.5 131.9  9.7 
Acute Exercise 89.9  6.6 114.4  7.3† 138.9  18.6* 148.6  21.2* 134.7  13.8 123.9  10.8 111.2  8.8 
Post Training 87.6  5.6 120.7  6.8† 145.2  17.9 150.7  20.2 133.5  11.6 116.9  7.3* 102.8  6.8* 
Glucose (mg/dL)       
Baseline 97.44.1 -- 127.58.9 -- 133.39.2 -- 107.37.1 
Acute Exercise 92.64.9 -- 118.95.0 -- 129.19.4 -- 113.04.8 
Post Training 93.86.4 -- 118.88.5 -- 122.73.8 -- 117.06.6 
Note: Data are presented as MSE. (*) significantly different from Baseline, p< 0.05. (†) significantly different from Baseline, p< 0.01.  
Table 13. Temporal Responses of plasma triglyceride concentration for High Step 
treatment during HFTT at Baseline, following a single bout of exercise (Acute), and 
following 5 training bouts over the 9-days of training (Post Training). (*) significantly 









Baseline H1 H2 H3 H4 H5 H6 
Triglycerides (mg/dL)       
Baseline 105.6  6.7 140.5  7.4 167.7  18.3 184.6  19.9 164.7  13.9 149.7  12.8 138.8  11.8 
Acute Exercise 112.6  11.0 148.5  12.4 175.3  22.2 191.6  23.9 171.5  18.0 154.5  15.2 139.2  15.9 
Post Training 105.5  7.3 140.4  7.4 162.6  14.5 176.6  14.0 155.4  16.4 140.3  11.4 124.7  11.0 
Glucose (mg/dL)       
Baseline 93.33.5 -- 118.27.1 -- 126.78.6 -- 121.210.5 
Acute Exercise 97.83.9 -- 135.6+12.5 -- 135.514.7 -- 118.88.6 
Post Training 97.12.7 -- 129.211.4 -- 134.511.3 -- 116.79.6 
Note: Data are presented as MSE.  
Table 14. Temporal Responses of plasma triglyceride concentration for Low Step 
treatment during High Fat Tolerance Test at Baseline, following a single bout of exercise 
(Acute), and following 5 training bouts over the 9-days of training (Post Training). Data 
reported MeanSE. 
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APPENDIX E: ADDITIONAL TABLES & FIGURES FOR STUDY 2  
 
 
Figure 13. Average daily steps were measured via activPal activity monitor, attached on 
the participant’s anterior thigh throughout each trial. Average daily step counts for each 
trial are presented for Control (C1 & C2) and Intervention Phases (D1 & D2). (*) 
significantly different from Low, p<0.05. (**) significantly different from Low, p<0.01. 
(†) significantly different from Low & Limited step trial, p<0.05.  
  


























Trial AUCT AUCI 
Triglycerides   
 Low 881.3  70.7 342.3  47.8 
 Limited 835.1  73.7 348.6  48.9 
 Normal 751.2  54.6† 267.5  39.2* 
Glucose   
 Low 709.1  46.8 159.2  35.2 
 Limited 678.7  37.7 126.4  25.8 
 Normal 683.0  23.6 124.9  20.6 
 
Table 15. Total and Incremental areas under the curve of plasma triglyceride & glucose 
concentrations during HFTT for each trial. (*) Significantly different from Low & 





APPENDIX F: BIHOURLY RER MEASUREMENTS 
 
Study 1 
Pairwise comparisons (Tables 9 &10) for time points during the HFTT indicated 
significant differences during the second hour for RER, percent fat and percent 




Baseline Acute Post Training 
Respiratory Exchange Ratio    
 Baseline 0.760  0.01 0.759  0.02 0.774  0.01 
 Hour 2 0.890  0.01† 0.833  0.01* 0.846  0.01 
 Hour 4 0.819  0.01 0.780  0.01 0.793  0.01 
 Hour 6 0.777  0.01 0.766  0.01 0.771  0.01 
Percent Fat Oxidation    
 Baseline 80.6  4.58 81.1  5.87 75.7  4.57 
 Hour 2 37.5  4.71† 57.0  4.13* 52.7  3.71 
 Hour 4 61.9  3.20 75.1  3.57 72.2  3.68 
 Hour 6 76.1  3.39 80.0  3.32 77.0  2.87 
Percent CHO Oxidation    
 Baseline 19.4  4.58 18.9  5.87 24.3  4.57 
 Hour 2 62.5  4.71† 43.0  4.13* 47.3  3.71 
 Hour 4 38.1  3.20 24.9  3.57 27.8  3.68 
 Hour 6 23.9  3.39 20.0  3.32 23.0  2.87 
Note: Data are presented as MSE 
Table 16.  Average postprandial substrate oxidation at each measurement for HS 
Treatment group. (*) Significantly different from Baseline, (p<0.05). All Data are 






Baseline Acute Post Training 
Respiratory Exchange Ratio    
 Baseline 0.773  0.01 0.754  0.01 0.760  0.02 
 Hour 2 0.879  0.01 0.879   0.01 0.861  0.01 
 Hour 4 0.826  0.02 0.793  0.1 0.814  0.01 
 Hour 6 0.789  0.02 0.779  0.01 0.763  0.01 
Percent Fat Oxidation    
 Baseline 76.2  4.44 86.9  3.19 80.6  5.14 
 Hour 2 41.4  3.83 41.4  2.52 47.3  3.02 
 Hour 4 59.5  5.26 70.7  4.06 68.3  6.74 
 Hour 6 72.2  5.39 75.6  4.91 76.1  2.95 
Percent CHO Oxidation    
 Baseline 23.8  4.44 13.1  3.19 19.4  5.14 
 Hour 2 58.6  3.83 58.6  2.52 52.7  3.02 
 Hour 4 40.5  5.26 29.3  4.06 31.7  6.74 
 Hour 6 27.8  5.39 24.4  4.91 23.9  2.95 
Note: Data are presented as MSE 
Table 17. Average postprandial substrate oxidation at each measurement for LS 







Low Limited Normal 
Respiratory Exchange Ratio    
 Baseline 0.782  0.010 0.750  0.007 0.739  0.006 
 Hour 2 0.844  0.018 0.833  0.014 0.793  0.011* 
 Hour 4 0.789  0.016 0.781  0.019 0.764  0.015 
 Hour 6 0.776  0.015 0.755  0.012 0.738  0.012 
Percent CHO Oxidation    
 Baseline 25.60  3.52 14.74  2.23 11.95  1.77 
 
Hour 2 
46.89  6.13 43.14  4.70 29.39  3.89* 
 Hour 4 28.05  5.58 25.12  6.49 18.09  5.48 
 Hour 6 23.62  5.09 16.52  4.17 11.26  4.16 
Percent Fat Oxidation    
 Baseline 74.40  3.52 85.26  2.23 88.05  1.77 
 Hour 2 53.11  6.13 56.86  4.70 70.61  3.89* 
 Hour 4 71.95  5.58 74.88  6.49 81.91  5.48 
 Hour 6 76.38  5.09 83.48  4.18 88.74  4.16 
Note: Data are presented as MSE (*) significantly different from both Low & Limited, p<0.05. 
Table 18. Average postprandial substrate oxidation at each measurement for each trial. 
(*) significantly different from both Low & Limited, p<0.05. All Data are reported as 





APPENDIX G:  STUDY 1 INDIVIDUAL DATA TABLES 
 
Biographical and VO2peak Data 





Pre Post Pre Post 
1 20 157.5 71.3 2364 2409 33.2 33.2 
2 21 168.9 74.2 2864 3320 38.6 45.2 
3 24 162.6 70.8 1547 1719 21.9 24.0 
4 21 172.7 79.9 2684 2986 33.6 37.0 
5 26 177.8 68.5 3242 3376 47.3 50.3 
6 21 162.6 62.2 1792 1788 28.8 28.7 
7 32 157.5 59.1 1431 1449 24.2 24.7 
8 25 177.8 94.9 2877 3089 30.3 33.0 
        





Pre Post Pre Post 
1 19 154.9 60.6 2321 2594 38.3 41.4 
2 35 167.6 94.1 2419 2569 25.7 27.6 
3 21 175.3 90.2 3875 3888 43.0 43.4 
4 26 167.6 91.25 2459 2517 26.9 28.3 
5 19 167.6 69.6 3126 3560 44.9 50.7 
6 18 177.8 68.25 2942 3098 43.1 46.1 
7 26 157.5 45.5 1312 1596 28.8 35.4 














Pre Post Pre Post Pre Post Pre Post 
1 115 1834 77.6 76.1 184 182 7.4 7.5 16 14 
2 164 2356 82.2 71 180 173 7.5 8.1 17 13 
3 75 1269 82.0 73.8 183 184 5.8 5.1 14 15 
4 148 2147 80.0 71.9 196 186 6.3 6.2 17 15 
5 175 2482 76.6 73.5 187 179 6.6 6.3 16 12 
6 91 1433 79.9 80.2 198 182 7.6 7.7 16 15 
7 70 1153 80.6 79.5 167 169 8.8 8.8 14 14 
8 167 2306 80.1 74.6 152 151 7.8 7.8 16 18 










Pre Post Pre Post Pre Post Pre Post 
1 119 1804 77.7 69.5 185 177 7.8 6.5 16 14 
2 132 1915 79.1 74.5 182 171 6.3 4.1 17 12 
3 222 3086 79.6 79.4 178 170 8.7 7.8 17 16 
4 130 1808 73.5 71.8 156 151 5.7 5.0 14 13 
5 176 2504 80.1 70.3 200 189 11.2 10.1 17 16 
6 165 2373 80.7 76.6 194 179 8.4 6.1 17 13 
7 55 1010 77.0 63.3 181 156 4.3 5.7 11 13 








1 2 3 4 5 6 7 8 
4 2489 2026 2446 4133 1576 7162 7836 4903 
5 2964 2130 4484 5564 1948 2926 5314 3979 
6 3821 4196 6190 3681 8420 7238 8748 840 
7 2004 3012 3255 2412 2622 3008 2651 3501 
8 2488 2564 4684 5281 1816 5894 5564 2783 
9 3602 2943 1352 3821 8066 9902 3936 2867 
10 4019 3620 11626 2013 8802 5194 9734 6305 
11 5473 2751 3201 5471 7198 2056 8364 4674 
12 5824 2416 8150 6882 7956 6768 8164 3325 
13 5722 2003 9766 7668 8984 5384 5616 7802 





1 2 3 4 5 6 7 8 
4 10855 13664 10756 20844 8800 15544 16002 13828 
5 11226 15886 13598 15802 8436 18244 15862 12630 
6 15896 15242 12584 21266 28880 24314 15578 10850 
7 17888 7896 8619 7926 15811 11829 8243 10557 
8 14956 12886 18286 15896 19210 17500 14996 12142 
9 14502 18952 30254 15890 16150 24584 13436 9538 
10 10661 11003 27204 16194 17816 26742 19022 13918 
11 11285 8004 32422 12570 8994 23268 16638 8670 
12 8656 15679 32974 21572 17368 18840 19002 14104 
13 9984 14898 17830 16824 15850 27264 16284 7884 




Plasma Triglyceride Concentrations 
Participant 
# 
LS TG Postprandial Time (Hours) 
Baseline H1 H2 H3 H4 H5 H6 
Baseline        
1 66.7 107.9 108.8 107.9 101.9 84.8 85.0 
2 119.5 148.1 168.5 211.3 200.0 172.0 144.0 
3 118.1 157.7 188.9 204.5 195.9 176.8 157.6 
4 109.3 158.5 189.4 207.9 189.2 183.5 177.9 
5 99.9 125.1 131.9 151.6 162.4 146.9 131.3 
6 92.1 116.5 122.5 115.6 105.6 109.0 112.4 
7 122.1 149.7 158.9 201.2 179.1 180.4 181.7 
8 116.8 160.4 272.6 276.9 183.5 144.3 120.3 
Acute        
1 58.2 94.7 95.4 97.8 93.3 87.9 75.4 
2 109.8 134.5 140.9 177.2 173.4 146.1 118.8 
3 158.0 198.7 221.1 231.0 195.5 187.2 178.9 
4 124.8 184.0 224.9 255.8 225.7 216.3 206.9 
5 110.4 137.0 145.3 149.3 139.0 126.6 114.3 
6 91.2 114.2 118.9 120.3 122.3 115.0 107.7 
7 145.5 168.8 173.7 208.5 180.7 181.0 181.3 
8 103.2 156.4 282.4 292.6 242.3 176.1 130.2 
Post Training       
1 83.2 124.8 120.9 136.4 123.1 110.6 77.4 
2 83.2 139.5 177.5 150.8 110.2 114.8 119.4 
3 122.2 155.5 170.5 211.3 210.0 186.4 162.8 
4 128.0 172.2 198.2 208.1 201.9 162.8 123.6 
5 93.1 118.2 125.0 155.6 121.8 119.0 116.3 
6 86.6 111.0 117.0 141.1 100.1 103.5 106.9 
7 122.3 149.8 159.1 164.8 172.3 173.9 175.6 







HS TG Postprandial Time (Hours) 
Baseline H1 H2 H3 H4 H5 H6 
Baseline        
1 78.0 133.2 145.5 157.8 133.9 120.5 125.5 
2 109.2 185.6 311.9 335.6 250.4 202.5 195.2 
3 99.3 139.4 139.6 139.5 127.8 128.1 114.4 
4 101.8 152.8 158.0 159.0 146.0 133.5 118.9 
5 96.6 138.4 136.5 149.2 148.9 144.9 142.8 
6 85.3 134.5 130.5 145.8 125.5 126.8 130.1 
7 90.1 136.7 139.9 146.0 129.6 121.3 113.0 
8 91.5 139.0 144.9 162.5 156.8 132.9 114.9 
Acute        
1 56.2 91.1 102.1 105.1 84.2 77.8 75.0 
2 109.5 148.5 260.7 290.6 199.5 157.3 125.0 
3 82.3 103.3 110.3 114.6 102.7 115.1 111.2 
4 104.2 111.9 122.4 129.0 139.4 120.5 113.9 
5 104.9 132.8 143.7 151.5 153.7 140.1 132.1 
6 96.5 104.3 114.4 124.8 123.1 115.9 104.7 
7 71.3 93.5 103.1 117.0 102.4 94.9 79.4 
8 94.1 129.9 154.4 156.4 172.3 169.4 148.0 
Post Training       
1 57.7 91.5 104.7 75.3 77.0 75.6 66.3 
2 79.9 153.8 261.9 276.0 192.4 149.7 127.9 
3 83.9 105.0 108.8 121.8 110.3 108.8 106.3 
4 93.5 127.9 138.7 159.7 134.5 123.4 117.2 
5 111.9 137.4 161.5 155.1 147.2 124.5 109.1 
6 100.4 119.8 136.6 142.6 132.6 119.0 110.5 
7 87.7 113.0 120.0 142.0 127.4 112.1 84.4 





Plasma Glucose Concentrations 
Participant 
# 
 LS Glucose Postprandial Time (Hours) 
Baseline H2 H4 H6 
Baseline     
1 92.7 126.9 169.7 132.5 
2 93.6 97.2 112.1 88.7 
3 77.7 160.4 95.7 92.5 
4 83.0 116.2 114.5 166.5 
5 101.8 105.7 121.9 96.5 
6 109.8 127.6 144.9 122.0 
7 96.1 106.0 110.1 112.6 
8 91.7 105.5 144.7 158.5 
Acute     
1 90.9 131.8 158.6 143.6 
2 93.1 103.1 119.0 90.4 
3 99.3 131.4 123.2 112.4 
4 87.0 121.9 122.4 134.5 
5 101.3 112.1 129.4 103.1 
6 116.2 203.4 228.5 160.2 
7 110.4 106.8 98.7 105.7 
8 84.5 174.4 104.1 100.6 
Post Training    
1 91.0 121.0 178.3 128.1 
2 88.8 93.0 90.3 82.1 
3 95.8 106.5 121.2 145.1 
4 100.5 140.6 144.9 159.6 
5 89.0 104.1 98.2 89.3 
6 109.5 196.2 175.6 104.8 
7 96.1 129.5 133.9 102.1 







HS Glucose Postprandial Time (Hours) 
Baseline H2 H4 H6 
Baseline     
1 103.3 124.3 125.4 107.9 
2 103.2 111.2 122.6 99.7 
3 86.5 101.8 115.2 97.1 
4 104.8 111.8 121.9 120.2 
5 114.9 176.0 125.6 91.2 
6 94.2 155.5 187.4 147.9 
7 78.3 124.9 157.6 84.0 
8 94.2 114.9 110.7 110.2 
Acute     
1 89.5 112.4 122.1 108.8 
2 98.1 112.5 184.9 92.8 
3 83.1 94.1 99.8 130.9 
4 100.2 120.1 123.3 113.1 
5 104.5 142.9 101.4 97.3 
6 106.4 128.3 137.2 112.7 
7 64.2 123.9 134.9 128.3 
8 95.1 117.4 129.5 120.2 
Post 
Training 
    
1 76.1 81.4 131.9 121.4 
2 95.8 151.9 118.3 113.2 
3 70.0 93.3 124.4 81.3 
4 98.8 132.2 120.8 123.9 
5 125.5 143.6 101.1 107.8 
6 90.0 120.6 134.7 123.6 
7 84.4 111.6 131.4 148.1 








LS RER Postprandial Time (Hours) 
Baseline H2 H4 H6 
Baseline     
1 0.78 0.9 0.88 0.86 
2 0.82 0.85 0.88 0.81 
3 0.8 0.87 0.79 0.77 
4 0.72 0.93 0.83 0.81 
5 0.75 0.85 0.78 0.77 
6 0.79 0.89 0.82 0.73 
7 0.75 0.86 0.8 0.77 
Acute     
1 0.77 0.88 0.83 0.84 
2 0.78 0.87 0.81 0.82 
3 0.72 0.9 0.8 0.76 
4 0.72 0.9 0.8 0.76 
5 0.75 0.85 0.78 0.77 
6 0.79 0.89 0.73 0.73 
7 0.75 0.86 0.8 0.77 
Post Training    
1 0.81 0.9 0.89 0.77 
2 0.77 0.88 0.8 0.78 
3 0.72 0.86 0.79 0.74 
4 0.78 0.84 0.8 0.79 
5 0.73 0.86 0.81 0.76 
6 0.71 0.86 0.81 0.71 







HS RER Postprandial Time (Hours) 
Baseline H2 H4 H6 
Baseline     
1 0.76 0.89 0.79 0.77 
2 0.79 0.91 0.85 0.81 
3 0.74 0.92 0.84 0.8 
4 0.71 0.88 0.79 0.77 
5 0.81 0.94 0.83 0.79 
6 0.78 0.84 0.8 0.77 
7 0.73 0.85 0.83 0.73 
Acute     
1 0.8 0.83 0.81 0.78 
2 0.77 0.89 0.81 0.75 
3 0.73 0.82 0.75 0.72 
4 0.71 0.85 0.77 0.76 
5 0.83 0.79 0.79 0.8 
6 0.71 0.84 0.79 0.77 
7 0.76 0.81 0.74 0.78 
Post Training    
1 0.77 0.8 0.79 0.74 
2 0.77 0.84 0.8 0.79 
3 0.83 0.87 0.76 0.81 
4 0.77 0.85 0.8 0.77 
5 0.81 0.89 0.81 0.76 
6 0.74 0.84 0.77 0.75 






Postprandial Fat Oxidation (kcal/6h) 
High Step 
 1 2 3 4 5 6 7 
Baseline 282.3 252.2 284.7 362.4 280.2 382.1 327.1 
Acute 312.2 277.8 446.2 444.4 433.8 388.8 385.4 
Post 
Training 
403.9 295.3 360.1 385.3 372.6 427.2 337.6 
 
Low Step 
 1 2 3 4 5 6 7 
Baseline 248.8 261.0 430.0 187.0 420.3 419.0 346.7 
Acute 245.8 269.7 312.8 275.2 548.1 474.7 336.2 
Post 
Training 




APPENDIX H:  STUDY 2 INDIVIDUAL DATA TABLES 
Biographical & Exercise Data 
Participant 
# 











1 20 71 94.1 3834 40.7 2438 63.6 134 12 4.3 
2 22 71 86.4 3999 46.3 2599 64.8 172 13 5.5 
3 32 61 54.6 1980 36.3 1287 65.2 139 10 4.4 
4 24 73 75.7 3233 42.7 2102 61.9 161 10 4.8 
5 21 62 73.5 2880 39.2 1868 64.8 166 11 4.6 
6 36 73 116.2 4658 40.1 3022 64.9 140 11 4.6 
7 32 67 84.1 3450 41.1 2284 66.2 153 12 4.5 
8 27 69 68.3 3213 47.0 2010 62.6 155 11 5.1 
9 19 66 66.1 2771 41.9 1896 65.2 159 13 4.1 




 Daily Steps 
Participant 
# 
Steps Day of Trial 
C1 C2 D1 D2 
Low     
1 5752 13302 1534 1006 
2 6076 9650 3594 904 
3 15844 13944 3365 3420 
4 9911 9063 2812 2292 
5 8891 10273 1305 3625 
6 5257 5712 2476 3169 
7 7805 8111 4610 3541 
8 8554 10841 1599 2210 
9 17886 19002 2833 3009 
10 16013 10254 3316 2881 
Limited     
1 4420 11826 3296 3484 
2 7906 7691 3921 5904 
3 10112 12248 5380 5078 
4 9225 5852 4801 4732 
5 10112 11540 6343 5203 
6 6661 8040 4470 5240 
7 7155 7440 4366 5110 
8 10185 11013 3937 4993 
9 16641 18145 3038 5728 
10 15662 11892 5265 4896 
Normal     
1 9003 7991 7853 8109 
2 8114 10846 5844 5730 
3 11550 14868 7578 8441 
4 8841 8857 6572 7880 
5 12208 11660 10571 9023 
6 5855 6827 7550 7827 
7 9194 7993 7191 8864 
8 10777 9945 8122 9751 
9 21016 15398 13856 8924 
10 14003 12933 9175 10751 
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 Plasma Triglyceride Concentrations 
Participant 
# 
TG Postprandial Time (Hours) 
Baseline H2 H3 H4 H6 
Low      
1 109.7 148.6 169.9 209.1 172.9 
2 113.1 179.4 169.7 175.4 157.8 
3 86.6 122.6 130.4 146.2 112.6 
4 98.6 152.3 158.7 142.8 124.0 
5 48.6 99.5 151.7 172.2 104.1 
6 124.5 232.1 260.1 299.6 231.3 
7 57.2 87.2 194.4 164.1 94.9 
8 85.6 138.0 137.1 130.5 117.6 
9 87.6 131.0 134.2 125.1 91.1 
10 86.9 184.8 217.5 199.9 124.2 
Limited      
1 103.9 139.4 182.2 197.6 161.5 
2 105.4 139.6 164.6 175.8 154.6 
3 83.8 114.4 137.9 130.7 108.4 
4 90.9 133.2 140.9 139.2 124.7 
5 40.3 81.2 149.4 136.8 68.0 
6 130.3 219.4 289.5 286.5 225.2 
7 38.6 120.1 213.3 194.3 115.7 
8 77.1 143.4 168.9 140.3 110.8 
9 66.1 118.5 116.5 102.2 79.6 
10 74.3 130.7 190.9 172.8 113.6 
Normal      
1 92.0 146.3 188.9 178.7 182.9 
2 111.4 147.3 155.1 156.4 134.7 
3 82.3 112.4 115.4 118.3 99.0 
4 83.6 129.9 134.4 121.6 118.9 
5 52.1 63.7 130.2 128.5 66.3 
6 89.3 175.0 221.0 214.9 168.3 
7 50.7 96.8 165.4 135.6 71.2 
8 75.3 127.7 127.5 106.8 93.2 
9 72.7 110.8 105.2 88.9 95.4 
10 90.1 143.2 169.9 166.5 126.6 
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 Plasma Glucose Concentrations 
Participant 
# 
Postprandial Time (Hours) 
Baseline H2 H3 H4 H6 
Low      
1 109.7 148.6 169.9 209.1 172.9 
2 113.1 179.4 169.7 175.4 157.8 
3 86.6 122.6 130.4 146.2 112.6 
4 98.6 152.3 158.7 142.8 124.0 
5 48.6 99.5 151.7 172.2 104.1 
6 124.5 232.1 260.1 299.6 231.3 
7 57.2 87.2 194.4 164.1 94.9 
8 85.6 138.0 137.1 130.5 117.6 
9 87.6 131.0 134.2 125.1 91.1 
10 86.9 184.8 217.5 199.9 124.2 
Limited      
1 103.9 139.4 182.2 197.6 161.5 
2 105.4 139.6 164.6 175.8 154.6 
3 83.8 114.4 137.9 130.7 108.4 
4 90.9 133.2 140.9 139.2 124.7 
5 40.3 81.2 149.4 136.8 68.0 
6 130.3 219.4 289.5 286.5 225.2 
7 38.6 120.1 213.3 194.3 115.7 
8 77.1 143.4 168.9 140.3 110.8 
9 66.1 118.5 116.5 102.2 79.6 
10 74.3 130.7 190.9 172.8 113.6 
Normal      
1 92.0 146.3 188.9 178.7 182.9 
2 111.4 147.3 155.1 156.4 134.7 
3 82.3 112.4 115.4 118.3 99.0 
4 83.6 129.9 134.4 121.6 118.9 
5 52.1 63.7 130.2 128.5 66.3 
6 89.3 175.0 221.0 214.9 168.3 
7 50.7 96.8 165.4 135.6 71.2 
8 75.3 127.7 127.5 106.8 93.2 
9 72.7 110.8 105.2 88.9 95.4 
10 90.1 143.2 169.9 166.5 126.6 
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 RER Data 
Participant 
# 
Postprandial Time (Hours) 
Baseline H2 H4 H6 
Low     
1 0.829 0.815 0.791 0.784 
2 0.809 0.774 0.747 0.741 
3 0.721 0.771 0.756 0.733 
4 0.814 0.836 0.798 0.761 
5 0.786 0.87 0.748 0.77 
6 0.786 0.848 0.761 0.796 
7 0.794 0.799 0.851 0.762 
8 0.772 0.947 0.898 0.885 
9 0.748 0.891 0.79 0.721 
10 0.761 0.923 0.812 0.809 
Limited     
1 0.764 0.776 0.714 0.697 
2 0.754 0.812 0.747 0.75 
3 0.72 0.831 0.772 0.744 
4 0.793 0.818 0.774 0.729 
5 0.726 0.851 0.763 0.751 
6 0.736 0.888 0.756 0.759 
7 0.745 0.848 0.827 0.794 
8 0.752 0.914 0.85 0.841 
9 0.757 0.781 0.908 0.752 
10 0.755 0.895 0.795 0.737 
Normal     
1 0.721 0.766 0.727 0.731 
2 0.724 0.777 0.791 0.718 
3 0.74 0.809 0.739 0.726 
4 0.743 0.789 0.741 0.723 
5 0.776 0.836 0.788 0.726 
6 0.717 0.755 0.757 0.735 
7 0.721 0.829 0.75 0.73 
8 0.745 0.844 0.732 0.735 
9 0.758 0.79 0.729 0.71 
10 0.748 0.736 0.886 0.844 
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Postprandial Fat Oxidation (kcal/6h) 
Participant 
Trial 1 2 3 4 5 6 7 8 9 10 
Baseline 417.8 512.5 522.6 417.8 512.5 522.6 417.8 512.5 522.6 417.8 
Acute 519.1 476.0 472.1 519.1 476.0 472.1 519.1 476.0 472.1 519.1 
Post 
Training 
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